@AponiaAnalytics aponia_analytics
Several biotech companies have recently made significant announcements. TG Therapeutics reported a strong Q3 revenue of $161.7m, driven by Briumvi sales, and raised its [----] guidance. Regeneron also posted a 13% increase in Q3 revenue to $3.68b, driven by Dupixent and Eylea HD. Additionally, Pfizer reported solid Q3 results, with a revenue of $16.7b and raised its [----] EPS guidance.
Engagements: [-----] #
- [--] Week [-------] +434%
- [--] Month [-------] -35%
- [--] Months [---------] +15%
- [--] Year [---------] +1,054%
Mentions: [--] #
- [--] Week [---] +98%
- [--] Month [---] -41%
- [--] Months [-----] +22%
- [--] Year [------] +717%
Followers: [-----] #
- [--] Week [-----] +0.65%
- [--] Month [-----] +0.73%
- [--] Months [-----] -0.43%
- [--] Year [-----] +72%
CreatorRank: [-------] #
Social Influence
Social category influence stocks 61.03% finance 19.72% currencies 1.88% technology brands 1.88% financial services 1.41% cryptocurrencies 1.41% celebrities 0.94% countries 0.94% fashion brands 0.47%
Social topic influence $hims #79, $ibrx #12, $nvo #45, $nwbo #11, novo 7.98%, $lly #26, in the 6.1%, health 4.69%, ceo 4.23%, $oscr #142
Top accounts mentioned or mentioned by @drpatrick @immunitybio @fda @saiseiinvesting @againstheliars @matthewherper @andrewdudum @pharmalot @benzinga @sanofis @damiangarde @lawliepop @michaeljburry @theroaringkitty @mhragovuk @davidwainer @saudifdaen @drmakaryfda @seckennedy @ablidy
Top assets mentioned Hims & Hers Health, Inc. (HIMS) ImmunityBio, Inc. Common Stock (IBRX) Novo-Nordisk (NVO) Eli Lilly and Company (LLY) Oscar Health, Inc. (OSCR) Sarepta Therapeutics, Inc. (SRPT) Viking Therapeutics, Inc (VKTX) Unicycive Therapeutics, Inc. (UNCY) UnitedHealth Group (UNH) Merck & Co., Inc. (MRK) Morgan Stanley (MS) Abivax SA (ABVX) Royalty Pharma plc (RPRX) Bristol-Myers Squibb Co (BMY) uniQure N.V. (QURE) Denali Therapeutics Inc. Common Stock (DNLI) Centessa Pharmaceuticals plc (CNTA) OnKure Therapeutics, Inc. (OKUR) Vaxcyte, Inc. (PCVX) Neumora Therapeutics, Inc. (NMRA) Regeneron Pharmaceuticals Inc (REGN) Synthetify (SNY) BridgeBio Pharma, Inc. Common Stock (BBIO) Agios Pharmaceuticals, Inc. (AGIO) Spruce Biosciences, Inc. (SPRB) Nuvalent, Inc. (NUVL)
Top Social Posts
Top posts by engagements in the last [--] hours
"$AGIO 🦉 Agios posted a $108M Q4 net loss as cash fell to $1.2B while PYRUKYND and newly launched AQVESME drove $20M in quarterly sales. The company heads into a pre-sNDA FDA meeting for mitapivat in sickle cell after reporting $54M full-year revenue. https://investor.agios.com/news-releases/news-release-details/agios-reports-fourth-quarter-and-full-year-2025-financial https://investor.agios.com/news-releases/news-release-details/agios-reports-fourth-quarter-and-full-year-2025-financial"
X Link 2026-02-12T19:44Z [----] followers, [--] engagements
"$NKTR $LLY $NKTR Here's a nugget from a friend. Two Seas Capital just bought a chunk of NKTR. Two Seas is a litigation-specialist investor (not a biotech investor). The fund's PM is an attorney. The $LLY trial starts in September and Two Seas sure seems to think that $NKTR is going to get https://t.co/PSuWbn3g2B $NKTR Here's a nugget from a friend. Two Seas Capital just bought a chunk of NKTR. Two Seas is a litigation-specialist investor (not a biotech investor). The fund's PM is an attorney. The $LLY trial starts in September and Two Seas sure seems to think that $NKTR is going to get"
X Link 2026-02-14T23:32Z [----] followers, [---] engagements
"$NKTR $NKTR bears will still look at you with a straight face and tell you that an adverse event (ISRs) that led to a LESS THAN 1% discontinuation rate is the bear thesis The ISR brain damage done to yall by those Lilly legal documents really is wild. Good biotech $NKTR bears will still look at you with a straight face and tell you that an adverse event (ISRs) that led to a LESS THAN 1% discontinuation rate is the bear thesis The ISR brain damage done to yall by those Lilly legal documents really is wild. Good biotech"
X Link 2026-02-15T14:51Z [----] followers, [---] engagements
"$BNTC 🦉 Benitec Biopharma priced a $100M stock offering at $13.50 per share including a direct sale to Suvretta Capital. Funds will advance its ddRNAi gene therapy programs and strengthen liquidity. #pressrelease https://www.benitec.com/for-investors/news-events/press-releases/detail/139/benitec-biopharma-inc-announces-pricing-of-100-million-common-stock-offering https://www.benitec.com/for-investors/news-events/press-releases/detail/139/benitec-biopharma-inc-announces-pricing-of-100-million-common-stock-offering"
X Link 2025-11-06T20:27Z [----] followers, [---] engagements
"$BNTC 🦉 Director Sharon Mates filed Form [--] on Nov [--] [----] disclosing no beneficial ownership in Benitec Biopharma following her appointment dated Nov [--] [----]. #form3 https://d1io3yog0oux5.cloudfront.net/benitec/sec/0001012975-25-000717/0001012975-25-000717.pdf https://d1io3yog0oux5.cloudfront.net/benitec/sec/0001012975-25-000717/0001012975-25-000717.pdf"
X Link 2025-11-08T18:07Z [----] followers, [---] engagements
"$SPRB 🦉Spruce Biosciences posted a Q3 [----] net loss of $8.2M as R&D spending fell to $5M after ending tildacerfont work. Cash totaled $10.7M extended to 4Q26 with $50M financing. #pressrelease #Q3 #report https://investors.sprucebio.com/news-releases/news-release-details/spruce-biosciences-reports-third-quarter-2025-financial-results https://investors.sprucebio.com/news-releases/news-release-details/spruce-biosciences-reports-third-quarter-2025-financial-results"
X Link 2025-11-10T21:11Z [----] followers, [---] engagements
"$NUVL 🦉 Officer Alexandra Balcom plans to sell [-----] shares via cashless exercise through J.P. Morgan on Nov [--] [----]. Previous sales include [----] shares on Sep [--] and [-----] shares on Sep [--] and Oct [--] each. #form_144 https://app.quotemedia.com/data/downloadFilingwebmasterId=101533&ref=319588239&type=HTML&symbol=NUVL&cdn=9d1424dad837ebcf7218d09df88e8090&companyName=Nuvalent+Inc.&formType=144&dateFiled=2025-11-17"
X Link 2025-11-17T21:45Z [----] followers, [---] engagements
"$CNTM 🦉 Contineum shares fell over 12% after PIPE-307 failed a mid-stage MS trial. Both doses were safe but showed no benefit on vision or secondary measures. The company will review exploratory data and present results later. https://www.biopharmadive.com/news/contineum-ms-trial-failure-johnson-johnson-neuroscience/806127/ https://www.biopharmadive.com/news/contineum-ms-trial-failure-johnson-johnson-neuroscience/806127/"
X Link 2025-11-21T17:43Z [----] followers, [---] engagements
"$AKBA $QTTB $AKBA $QTTB Akebia Announces Establishment of Rare Kidney Disease Pipeline - QTTB BioPharmCatalyst https://t.co/L22GgQEWAC $AKBA $QTTB Akebia Announces Establishment of Rare Kidney Disease Pipeline - QTTB BioPharmCatalyst https://t.co/L22GgQEWAC"
X Link 2025-12-01T20:22Z [----] followers, [---] engagements
"$RPRX $DNLI $RPRX $DNLI Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement BioPharmCatalyst https://t.co/wGUQ4rSYTI $RPRX $DNLI Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement BioPharmCatalyst https://t.co/wGUQ4rSYTI"
X Link 2025-12-04T17:33Z [----] followers, [---] engagements
"$DNLI $RPRX $DNLI and $RPRX Announce $275 Million Royalty Funding Agreement https://t.co/IsG6su0xFN $DNLI and $RPRX Announce $275 Million Royalty Funding Agreement https://t.co/IsG6su0xFN"
X Link 2025-12-04T17:39Z [----] followers, [---] engagements
"$KURA 🚀🚨 BIOPHARM CATALYST ALERT 📆 $KURA Kura Oncology will present Phase [--] Acute Myeloid Leukemia Data for Ziftomenib (MEN1 Inhibitor - Small Molecule) tomorrow 👀 🚀🚨 BIOPHARM CATALYST ALERT 📆 $KURA Kura Oncology will present Phase [--] Acute Myeloid Leukemia Data for Ziftomenib (MEN1 Inhibitor - Small Molecule) tomorrow 👀"
X Link 2025-12-07T15:46Z [----] followers, [---] engagements
"$ONC 🦉 BeOne flags standout ASH data: BRUKINSA hit 74% six-year PFS in frontline CLL and topped ibrutinib in long-term R/R follow-up. And BTK degrader BGB-16673 posted 85% ORR in heavily pretreated CLL. https://ir.beonemedicines.com/news/brukinsa-delivers-landmark-74percent-6-year-pfs-in-patients-with-treatment-naive-chronic-lymphocytic-leukemia/f08c351c-db37-4f8f-a8e6-8b76ecd55f58 https://ir.beonemedicines.com/news/brukinsa-delivers-landmark-74percent-6-year-pfs-in-patients-with-treatment-naive-chronic-lymphocytic-leukemia/f08c351c-db37-4f8f-a8e6-8b76ecd55f58"
X Link 2025-12-08T20:28Z [----] followers, [---] engagements
"$CGEM 🦉 Cullinan rolled into ASH with CLN-049 data showing multiple complete responses and a clean safety read. And the FDA just stamped it Fast Track tightening the spotlight on this AML program. https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-showcases-compelling-clinical-data-aml-cln https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-showcases-compelling-clinical-data-aml-cln"
X Link 2025-12-08T20:32Z [----] followers, [---] engagements
"$PRAX 🦉 Praxis clears its FDA talks and plans an early-2026 NDA for relutrigine in SCN2A and SCN8A epileptic encephalopathies. The filing leans on EMBOLD data showing statistically meaningful treatment effects. https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-plans-file-nda-relutrigine https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-plans-file-nda-relutrigine"
X Link 2025-12-11T19:09Z [----] followers, [---] engagements
"$CNTA 🦉 Centessa names Mario Accardi CEO as it pivots fully to its orexin franchise effective Jan. [--] [----]. Outgoing chief Saurabh Saha becomes advisor while ORX750 heads toward a Q1 [----] registrational start. https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-ceo-transition-company https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-ceo-transition-company"
X Link 2025-12-11T19:13Z [----] followers, [---] engagements
"$SDGR 🦉Schrdinger granted RSUs covering [----] shares to six new hires on Dec. [--] under its [----] inducement plan. Awards vest over four years starting with 25% after year one. https://ir.schrodinger.com/press-releases/news-details/2025/Schrdinger-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635c4-ff9b7e0d0/default.aspx https://ir.schrodinger.com/press-releases/news-details/2025/Schrdinger-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635c4-ff9b7e0d0/default.aspx"
X Link 2025-12-17T18:48Z [----] followers, [---] engagements
"$OKUR 🦉 CEO Nicholas Saccomano sold [--] shares at $2.97 to cover RSU tax withholding. Post-transaction ownership totals [----] shares per filing. #form_4 https://onkuretherapeutics.gcs-web.com/static-files/def41edf-4764-480a-b892-155b1032652a https://onkuretherapeutics.gcs-web.com/static-files/def41edf-4764-480a-b892-155b1032652a"
X Link 2025-12-24T21:23Z [----] followers, [---] engagements
"$PCVX 🦉 Officer Elvia Cowan filed a Form [---] to sell [-----] shares about $557k via Morgan Stanley. Stock stems from RSUs and option exercises with sale slated for Dec. [--]. #form_144"
X Link 2025-12-24T22:22Z [----] followers, [---] engagements
"$GMAB #portfolio #update 🦉 Genmab is pulling the plug on acasunlimab after a portfolio reset despite encouraging data. Capital shifts to EPKINLY petosemtamab and Rina-S with [----] guidance left untouched. https://ml-eu.globenewswire.com/Resource/Download/d61a4b07-4b51-43bb-a463-e1911f63e6e9 https://ml-eu.globenewswire.com/Resource/Download/d61a4b07-4b51-43bb-a463-e1911f63e6e9"
X Link 2025-12-29T17:41Z [----] followers, [---] engagements
"$UNCY $UNCY resubmits Oxylanthanum Carbonate (OLC) NDA $UNCY resubmits Oxylanthanum Carbonate (OLC) NDA"
X Link 2025-12-29T17:54Z [----] followers, [---] engagements
"$RPRX $RPRX Acquires Remaining Royalty Interest in Roches Evrysdi for $240M and Potential Milestones $RPRX Acquires Remaining Royalty Interest in Roches Evrysdi for $240M and Potential Milestones"
X Link 2025-12-30T15:44Z [----] followers, [---] engagements
"$NMRA Small signal-seeking Phase 1b shows a modest overall effect on CMAI with a moderate signal only in an anxiety-enriched subgroup. $NMRA Clean safety and no sedation are positives but subgroup-dependence subjective endpoints and an outlier-exclusion in placebo are the bear Small signal-seeking Phase 1b shows a modest overall effect on CMAI with a moderate signal only in an anxiety-enriched subgroup. $NMRA Clean safety and no sedation are positives but subgroup-dependence subjective endpoints and an outlier-exclusion in placebo are the bear"
X Link 2026-01-05T14:55Z [----] followers, [---] engagements
"$NMRA $NMRA Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimers Disease Agitation https://t.co/FdvzZI1pUU $NMRA Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimers Disease Agitation https://t.co/FdvzZI1pUU"
X Link 2026-01-05T15:21Z [----] followers, [---] engagements
"$INCY Control in $INCY Frontmind (1st-line DLBCL) is R-Chop not Revlimid + R-Chop. So how do we know the (modest) PFS benefit toplined today is due to $INCY Monjuvi and not to Revlimid https://t.co/Swc41ElHFr Control in $INCY Frontmind (1st-line DLBCL) is R-Chop not Revlimid + R-Chop. So how do we know the (modest) PFS benefit toplined today is due to $INCY Monjuvi and not to Revlimid https://t.co/Swc41ElHFr"
X Link 2026-01-05T16:36Z [----] followers, [---] engagements
"$EXEL $NTRA 🦉 Exelixis brings Nateras Signatera into STELLAR-316 steering a Phase [--] CRC trial toward MRD-positive patients. Zanzalintinib alone or with immunotherapy is slated to start mid-2026. https://ir.exelixis.com/news-releases/news-release-details/exelixis-and-natera-collaborate-stellar-316-phase-3-pivotal https://ir.exelixis.com/news-releases/news-release-details/exelixis-and-natera-collaborate-stellar-316-phase-3-pivotal"
X Link 2026-01-07T16:55Z [----] followers, [---] engagements
"$RZLT 🦉 Rezolutes Phase [--] sunRIZE study missed endpoints in congenital hyperinsulinism but biomarker signals and OLE data suggest drug activity. Tumor HI EAP showed 75% off IV glucose with FDA talks slated Q1. https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism"
X Link 2026-01-07T18:00Z [----] followers, [---] engagements
"$NBP $NBP (formerly called I-Mab) announced positive updated results from the Phase 1b combination study of givastomig a Claudin [----] (CLDN18.2) x 4-1BB bispecific antibody in combination with nivolumab and chemotherapy (mFOLFOX6) in patients with HER2-negative first line (1L) https://t.co/Pr9lOoUqIe $NBP (formerly called I-Mab) announced positive updated results from the Phase 1b combination study of givastomig a Claudin [----] (CLDN18.2) x 4-1BB bispecific antibody in combination with nivolumab and chemotherapy (mFOLFOX6) in patients with HER2-negative first line (1L) https://t.co/Pr9lOoUqIe"
X Link 2026-01-07T18:12Z [----] followers, [--] engagements
"$CYTK $BMY $EWTX Jefferies $CYTK's PT to $90 from $80 reiterated at Buy and said CYTK's upcoming Ph.3 study ACACIA in non-obstructive HCM (nHCM) is one of the biggest readouts in SMID cap biotech in 1H'26. $BMY $EWTX Jefferies added If successful it could open up aficamten in nHCM which Jefferies $CYTK's PT to $90 from $80 reiterated at Buy and said CYTK's upcoming Ph.3 study ACACIA in non-obstructive HCM (nHCM) is one of the biggest readouts in SMID cap biotech in 1H'26. $BMY $EWTX Jefferies added If successful it could open up aficamten in nHCM which"
X Link 2026-01-09T15:58Z [----] followers, [---] engagements
"$BNTC 🦉 BB-301 didnt fade with time: the first OPMD patient kept improving two years after dosing. All four Cohort [--] patients still cleared responder bars at [--] months pointing to durable effect. https://www.benitec.com/for-investors/news-events/press-releases/detail/141/benitec-biopharma-provides-positive-long-term-clinical-study-results-for-bb-301-phase-1b2a-clinical-trial-demonstrating-robust-efficacy-and-continued-durability-of-response"
X Link 2026-01-11T16:58Z [----] followers, [---] engagements
"$OMDA JUST IN: $OMDA announces preliminary Q4 results. Revenue of $72-74M vs. $69M est. 🟢 Total members at 886k up 55% YoY Both metrics accelerated further from Q3 exactly as I predicted in my recent article. The company expects to report final results on March [--] after market https://t.co/aEAMtPBa14 JUST IN: $OMDA announces preliminary Q4 results. Revenue of $72-74M vs. $69M est. 🟢 Total members at 886k up 55% YoY Both metrics accelerated further from Q3 exactly as I predicted in my recent article. The company expects to report final results on March [--] after market https://t.co/aEAMtPBa14"
X Link 2026-01-12T20:05Z [----] followers, [---] engagements
"$ABVX 🦉 Sofinnova cut its Abivax stake to 7.7% voting power after selling 684k ADS across Jan [----] at $118142. The group still holds 3.33M shares and 6.4M voting rights post-sale. #form_13D https://ir.abivax.com/static-files/0319d5cf-bd14-4c7f-93b3-b04887bc8bb3 https://ir.abivax.com/static-files/0319d5cf-bd14-4c7f-93b3-b04887bc8bb3"
X Link 2026-01-14T22:21Z [----] followers, [---] engagements
"$CNTA #Centessa 🦉 Centessa showed preclinical data at ACNP where OX2R activation cut depressive-like behavior and boosted wakefulness in animal models. The results support expanding its orexin pipeline beyond hypersomnia into neuropsychiatric disease. https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-poster-presentation-new https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-poster-presentation-new"
X Link 2026-01-15T18:36Z [----] followers, [---] engagements
"$ABVX $PALI $SYRE $ABVX $PALI $SYRE BTIG IBD catalysts we care about in 2026: ABVX 52wk Phase [--] ABTECT results (late 2Q26) ABVX Phase 2b Crohn's disease induction data (late 2026) SYRE Phase [--] monotherapy UC data (starting in 2Q26) potential initiation of Tremfya +golimumab Phase [--] trials $ABVX $PALI $SYRE BTIG IBD catalysts we care about in 2026: ABVX 52wk Phase [--] ABTECT results (late 2Q26) ABVX Phase 2b Crohn's disease induction data (late 2026) SYRE Phase [--] monotherapy UC data (starting in 2Q26) potential initiation of Tremfya +golimumab Phase [--] trials"
X Link 2026-01-25T17:49Z [----] followers, [----] engagements
"$JNXT 🦉 Janux Therapeutics names William Go ex-Kite and A2 Bio CMO effective Jan [--] replacing Zachariah McIver. Go led ZUMA-1 to Yescarta FDA/EMA approval and joins as JANX007 and JANX008 run Phase [--]. https://investors.januxrx.com/investor-media/news/news-details/2026/Janux-Therapeutics-Appoints-William-Go-M-D--Ph-D--as-Chief-Medical-Officer/default.aspx https://investors.januxrx.com/investor-media/news/news-details/2026/Janux-Therapeutics-Appoints-William-Go-M-D--Ph-D--as-Chief-Medical-Officer/default.aspx"
X Link 2026-01-26T19:36Z [----] followers, [--] engagements
"#Sarepta $SRPT 🦉 Three years after a single dose kids with Duchenne treated with ELEVIDYS were still walking better than expected. The usual decline slowedby about 70%. That gap kept widening with time. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-positive-topline-three-year-embark-results https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-positive-topline-three-year-embark-results"
X Link 2026-01-26T20:07Z [----] followers, [---] engagements
"#Sarepta $SRPT 🦉 At age nine when Duchenne typically speeds up boys in the EMBARK study stayed above their starting strength. Controls slipped. Gene therapy changed the curve not just the score. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-positive-topline-three-year-embark-results https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-positive-topline-three-year-embark-results"
X Link 2026-01-26T20:08Z [----] followers, [---] engagements
"$MIRM #FDA 🦉 Mirum Pharmaceuticals closed its Bluejay acquisition adding brelovitug for HDV with FDA Breakthrough and EMA PRIME tags. Phase [--] AZURE topline data are expected in 2H [----] backed by a $268.5M financing. https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Completes-Acquisition-of-Bluejay-Therapeutics-Expanding-Global-Leadership-in-Rare-Disease/default.aspx https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Completes-Acquisition-of-Bluejay-Therapeutics-Expanding-Global-Leadership-in-Rare-Disease/default.aspx"
X Link 2026-01-26T20:15Z [----] followers, [---] engagements
"#Sarepta $SRPT"
X Link 2026-01-26T20:18Z [----] followers, [---] engagements
"$SRPT #Sarepta 🦉 Sarepta Therapeutics was upgraded to Zacks Rank #2 after earnings estimates rose 24.6% in three months. FY2025 EPS is still seen at $2.31 unchanged year over year. https://finance.yahoo.com/news/sarepta-therapeutics-srpt-upgraded-buy-170004126.html https://finance.yahoo.com/news/sarepta-therapeutics-srpt-upgraded-buy-170004126.html"
X Link 2026-01-26T20:28Z [----] followers, [---] engagements
"$RGNX #FDA 🦉 FDA placed clinical holds on RGX-111 and RGX-121 after a CNS tumor was detected in one RGX-111 patient. Causality is unestablished; both MPS programs are paused pending FDA review. #form_8K https://ir.regenxbio.com/static-files/58f6ab0b-debc-423f-9732-aed286f252a8 https://ir.regenxbio.com/static-files/58f6ab0b-debc-423f-9732-aed286f252a8"
X Link 2026-01-28T18:18Z [----] followers, [---] engagements
"$GUTS #FDA $GUTS requested FDA feedback on potentially reclassifying Revita under the De Novo pathway rather than a PMA. Expects FDA feedback regarding the potential for use of the De Novo pathway in Q2 $GUTS requested FDA feedback on potentially reclassifying Revita under the De Novo pathway rather than a PMA. Expects FDA feedback regarding the potential for use of the De Novo pathway in Q2"
X Link 2026-01-29T15:53Z [----] followers, [--] engagements
"$UNCY #FDA $UNCY FDA Accepts Oxylanthanum Carbonate (OLC) NDA Resubmission. PDUFA 06/27/26 $UNCY FDA Accepts Oxylanthanum Carbonate (OLC) NDA Resubmission. PDUFA 06/27/26"
X Link 2026-01-29T18:19Z [----] followers, [---] engagements
"$ROG $RHHBY 🦉 Roche booked CHF61.5B in [----] sales up 7% CER with Phesgo Ocrevus and Vabysmo carrying growth. Core profit rose 13% and the board put up a CHF9.80 dividend while guiding [----] to mid-single-digit CER gains. https://www.roche.com/investors/updates/inv-update-2026-01-29 https://www.roche.com/investors/updates/inv-update-2026-01-29"
X Link 2026-01-29T18:33Z [----] followers, [--] engagements
"$UNCY @FDA 🦉 Jan [--] 2026: FDA accepted OLC NDA resubmission; set PDUFA June [--] [----]. Agency classified as Class II CRL; six-month review. Company reported $41.3M cash at [----] end runway into [----]. https://ir.unicycive.com/news/detail/117/unicycive-therapeutics-announces-fda-acceptance-of https://ir.unicycive.com/news/detail/117/unicycive-therapeutics-announces-fda-acceptance-of"
X Link 2026-01-29T18:44Z [----] followers, [--] engagements
"$UNCY 🦉 Jan [--] 2026: Unicycive Therapeutics said U.S. Food and Drug Administration accepted its OLC NDA resubmission and set a June [--] [----] PDUFA date. Filing marked Class II with six-month review. Company reported $41.3M cash at [----] end. https://ir.unicycive.com/news/detail/118/update---unicycive-therapeutics-announces-fda-acceptance-of https://ir.unicycive.com/news/detail/118/update---unicycive-therapeutics-announces-fda-acceptance-of"
X Link 2026-01-29T18:58Z [----] followers, [--] engagements
"$PALI 🦉 Franklin Resources and affiliated entities reported a combined [-------] shares (6.0% of class) beneficially owned in Palisade Bio as of Dec [--] [----] under a Schedule 13G. Ownership includes warrants exercisable for [-------] shares. #form_13G https://s3.amazonaws.com/sec.irpass.cc/2827/0000038777-26-000014.htm https://s3.amazonaws.com/sec.irpass.cc/2827/0000038777-26-000014.htm"
X Link 2026-01-29T19:06Z [----] followers, [---] engagements
"$BNTC 🦉 Franklin Resources reported [-------] Benitec shares a 10.6% stake including [-------] warrant shares. Voting and dispositive power sit with Franklin Advisers as investment manager. #form_13G https://d1io3yog0oux5.cloudfront.net/benitec/sec/0000038777-26-000024/0000038777-26-000024.pdf https://d1io3yog0oux5.cloudfront.net/benitec/sec/0000038777-26-000024/0000038777-26-000024.pdf"
X Link 2026-01-29T19:14Z [----] followers, [--] engagements
"$UNCY $UNCY: The Class II designation and a tough day for the indexes $IWM explains todays volatility. FDA accepted the OLC resubmission as Class II with a PDUFA target 6/27/26a longer review window not a clinical negative. Cash was $41.3M at YE25 with stated runway into [----] $UNCY: The Class II designation and a tough day for the indexes $IWM explains todays volatility. FDA accepted the OLC resubmission as Class II with a PDUFA target 6/27/26a longer review window not a clinical negative. Cash was $41.3M at YE25 with stated runway into 2027"
X Link 2026-01-29T19:29Z [----] followers, [---] engagements
"$QURE #uniQure 🦉 Aberdeen Group and abrdn report [-------] uniQure shares a 5.91% stake. Voting and dispositive power are shared across the position. #form_13G https://uniqure.gcs-web.com/static-files/9b64fb3c-5db0-434b-beb2-ff5b78205abc https://uniqure.gcs-web.com/static-files/9b64fb3c-5db0-434b-beb2-ff5b78205abc"
X Link 2026-01-29T22:11Z [----] followers, [---] engagements
"$SRPT 🦉 Director Kathleen Behrens exercised [-----] options at $13.71 on Jan.27. She disposed [----] shares at $22.17 for taxes; holds [------] direct. #form_4 https://investorrelations.sarepta.com/static-files/497700f3-1eb7-42bc-8960-c895b3c011aa https://investorrelations.sarepta.com/static-files/497700f3-1eb7-42bc-8960-c895b3c011aa"
X Link 2026-01-30T15:15Z [----] followers, [---] engagements
"$PCVX 🦉Priced 11M shares at $50 for $550M gross Jan 29; grants 30-day option for 1.65M more; deal set to close Feb [--]. https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-announces-pricing-550-million-public-offering https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-announces-pricing-550-million-public-offering"
X Link 2026-01-30T15:35Z [----] followers, [--] engagements
"$SRPT 🦉 Claude Nicaise exercised [-----] options at $13.71 Jan.29. [----] shares were withheld at $21.23 for taxes; [-----] shares remain direct. #form_4 https://investorrelations.sarepta.com/static-files/75649577-ec3e-40e1-8354-727e26eb03ff https://investorrelations.sarepta.com/static-files/75649577-ec3e-40e1-8354-727e26eb03ff"
X Link 2026-01-30T15:42Z [----] followers, [---] engagements
"$REGN 🦉 Regeneron Reports Fourth Quarter and Full Year [----] Financial and Operating Results Q4 revenue rose 3% to $3.9B; FY up 1% to $14.3B. Dupixent sales jumped 34% to $4.9B while total U.S. EYLEA franchise sales fell 28%. https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2025-financial https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2025-financial"
X Link 2026-01-30T16:50Z [----] followers, [--] engagements
"$OKUR 🦉 Vanguard reports [------] OnKure shares equal to a 4.87% stake. Disposition power is shared across the position with only limited shared voting rights. #form_13G https://onkuretherapeutics.gcs-web.com/static-files/092b89f7-0253-466e-afe0-da0b1f6205fe https://onkuretherapeutics.gcs-web.com/static-files/092b89f7-0253-466e-afe0-da0b1f6205fe"
X Link 2026-01-30T20:00Z [----] followers, [--] engagements
"$UNH $UNH 🐳🚨 🚨Monster accumulation: 1.3M+ shares in [--] blocks within an hour and a half midday buyers paid premiums up to $1.01 over ask on blocks 164k400k. $373M notional scooped on💰 🐂For a $500B+ market cap name like UNH this kind of size on dips (post-earnings/guidance https://t.co/cvQPF3U3F2 $UNH 🐳🚨 🚨Monster accumulation: 1.3M+ shares in [--] blocks within an hour and a half midday buyers paid premiums up to $1.01 over ask on blocks 164k400k. $373M notional scooped on💰 🐂For a $500B+ market cap name like UNH this kind of size on dips (post-earnings/guidance https://t.co/cvQPF3U3F2"
X Link 2026-01-31T21:29Z [----] followers, [---] engagements
"$WVE This is the Grade [--] SAE version of "our partner doesn't like or want our drug so they gave it back." Wave Life Sciences $WVE announces plans to accelerate regulatory engagement with full control of WVE-006 for alpha-1 antitrypsin deficiency This is the Grade [--] SAE version of "our partner doesn't like or want our drug so they gave it back." Wave Life Sciences $WVE announces plans to accelerate regulatory engagement with full control of WVE-006 for alpha-1 antitrypsin deficiency"
X Link 2026-02-02T14:55Z [----] followers, [--] engagements
"$SRPT #Sarepta"
X Link 2026-02-05T23:43Z [----] followers, [---] engagements
"$MRK $PFE $AMGN $REGN $NWBO 🧭 The Tail They Learned to Trust Two #KEYTRUDA Alumni and One Immune Architecture Linking #DCVax-L with $MRK $PFE $AMGN $REGN and $NWBO into a Converging #immunotherapy Operating System Arun Balakumaran and Kevin Duffy matter here for a forensic reason: they were trained 🧭 The Tail They Learned to Trust Two #KEYTRUDA Alumni and One Immune Architecture Linking #DCVax-L with $MRK $PFE $AMGN $REGN and $NWBO into a Converging #immunotherapy Operating System Arun Balakumaran and Kevin Duffy matter here for a forensic reason: they were trained"
X Link 2026-02-06T13:08Z [----] followers, [---] engagements
"$HIMS #GLP1 In an emergency Hims House episode Crmieux joined Jonathan Stern to discuss all things $HIMS GLP-1s and the legalities of everything that unfolded today between Hims Novo Nordisk and the FDA. This clip summarizes their conversation. https://t.co/LscFxvpA0m In an emergency Hims House episode Crmieux joined Jonathan Stern to discuss all things $HIMS GLP-1s and the legalities of everything that unfolded today between Hims Novo Nordisk and the FDA. This clip summarizes their conversation. https://t.co/LscFxvpA0m"
X Link 2026-02-06T13:20Z [----] followers, [---] engagements
"$QURE 🦉 "uniQure paused mid- and high-dose AMT-191 dosing after an independent committee classified Grade [--] liver enzyme elevations as dose-limiting toxicity" https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-updated-preliminary-amt-191-phase-iiia-data https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-updated-preliminary-amt-191-phase-iiia-data"
X Link 2026-02-06T20:57Z [----] followers, [---] engagements
"$BNTX #FixVac $BMY #GVAX $NWBO #DCVax 🧬 THREE WAYS TO TEACH THE IMMUNE SYSTEM TO FIGHT CANCER AND WHY DENDRITIC CELLS DECIDE THE OUTCOME $BNTX #FixVac $BMY #GVAX and $NWBO #DCVax are a clean comparison because they sit on the same axis: all three depend on dendritic cells but they place the teaching job in 🧬 THREE WAYS TO TEACH THE IMMUNE SYSTEM TO FIGHT CANCER AND WHY DENDRITIC CELLS DECIDE THE OUTCOME $BNTX #FixVac $BMY #GVAX and $NWBO #DCVax are a clean comparison because they sit on the same axis: all three depend on dendritic cells but they place the teaching job in"
X Link 2026-02-06T21:33Z [----] followers, [---] engagements
"$IBRX #ANKTIVA In this JAMA study of over [-----] Americans a clear demonstration of survival related to lymphocyte levels is seen in this graph. When lymphocyte levels fall between [---] to [---] the survival rate plummets. ALC matters https://t.co/1o0eaQ4K7M https://t.co/hMuiuUrVyc In this JAMA study of over [-----] Americans a clear demonstration of survival related to lymphocyte levels is seen in this graph. When lymphocyte levels fall between [---] to [---] the survival rate plummets. ALC matters https://t.co/1o0eaQ4K7M https://t.co/hMuiuUrVyc"
X Link 2026-02-06T21:59Z [----] followers, [----] engagements
"$HIMS $NVO 🦉 FDA said its ready to act on illegal copycat drugs after Hims rolled out a $49 compounded Wegovy pill; Novo says a lawsuit is coming. Compounded GLP-1s had lived in a shortage loophole. That shelter looks thinner. https://ts2.tech/en/hims-hers-hims-stock-slips-again-as-49-wegovy-copy-draws-fda-heat-and-novo-legal-threat/ https://ts2.tech/en/hims-hers-hims-stock-slips-again-as-49-wegovy-copy-draws-fda-heat-and-novo-legal-threat/"
X Link 2026-02-06T22:13Z [----] followers, [---] engagements
"$OSCR [--] days before $OSCR earnings. I want to remember Bright Health. Same playbook. Tech-first ACA insurer IPO'd in [----] massive growth ambitions. Bright hit 103% MLR burned through hundreds of millions and is gone from the market. They rebranded sold off the pieces and went https://t.co/bk1F6dzdQz [--] days before $OSCR earnings. I want to remember Bright Health. Same playbook. Tech-first ACA insurer IPO'd in [----] massive growth ambitions. Bright hit 103% MLR burned through hundreds of millions and is gone from the market. They rebranded sold off the pieces and went https://t.co/bk1F6dzdQz"
X Link 2026-02-07T19:18Z [----] followers, [---] engagements
"$HIMS $NVO The Streisand Effect in action with $HIMS and $NVO 👇 The Streisand Effect occurs when an attempt to suppress censor or discredit information (or a product) backfires spectacularly drawing far more public attention to it than would have happened otherwise. Heres how its https://t.co/pgMd2wpLTa The Streisand Effect in action with $HIMS and $NVO 👇 The Streisand Effect occurs when an attempt to suppress censor or discredit information (or a product) backfires spectacularly drawing far more public attention to it than would have happened otherwise. Heres how its https://t.co/pgMd2wpLTa"
X Link 2026-02-07T19:35Z [----] followers, [---] engagements
"$HIMS $NVO $HIMS has more than 2X the performance of $NVO since going public in late [----]. $HIMS +132% $NVO +63% Hims is a health disruptor Novo Nordisk do not like it and continue to threaten to sue Hims because they are a clear threat. $HIMS isn't going anywhere and will continue https://t.co/d70OqdAUcs $HIMS has more than 2X the performance of $NVO since going public in late [----]. $HIMS +132% $NVO +63% Hims is a health disruptor Novo Nordisk do not like it and continue to threaten to sue Hims because they are a clear threat. $HIMS isn't going anywhere and will continue"
X Link 2026-02-07T19:57Z [----] followers, [---] engagements
"$HIMS #FDA $NVO Prediction: [--]. $HIMS turns quarrel with FDA and $NVO into massive marketing campaign with SuperBowl Ad. [--]. Ends in a fine. [--]. Business does fine long term. Prediction: [--]. $HIMS turns quarrel with FDA and $NVO into massive marketing campaign with SuperBowl Ad. [--]. Ends in a fine. [--]. Business does fine long term"
X Link 2026-02-07T20:01Z [----] followers, [---] engagements
"$QURE $SGMO $SNY $IDEA [--] week [--] #Fabry headlines from #worldsymposium $SNY Fabry #fails to meet expectations $IDEA no renal benefit in Fabry $QURE Fabry #stops dosing on #tox do not report eGFR #high variability path forwar #unclear. $SGMO cures Fabry and stabilizes cardiac functions https://t.co/MiDhbP8tDx [--] week [--] #Fabry headlines from #worldsymposium $SNY Fabry #fails to meet expectations $IDEA no renal benefit in Fabry $QURE Fabry #stops dosing on #tox do not report eGFR #high variability path forwar #unclear. $SGMO cures Fabry and stabilizes cardiac functions https://t.co/MiDhbP8tDx"
X Link 2026-02-07T20:08Z [----] followers, [---] engagements
"$HIMS $NVO 🦉 Hims & Hers halts $49 Wegovy copycat pill after FDA threatened action. The telehealth firm reversed course days after launching the semaglutide offering as regulators warned of safety and legal risks"
X Link 2026-02-07T23:32Z [----] followers, [---] engagements
"$HIMS $NVO 🚨 NOVO NORDISK vs. $HIMS & HERS The lawsuit is [---] pages Filed in the US District Court for the District of Delaware It is a patent-only lawsuit; Novo is NOT suing for trademark or advertising issues The patent at issue is U.S. Patent No. [-------] ('343 patent) -- Novo's https://t.co/a4cszxRkcz 🚨 NOVO NORDISK vs. $HIMS & HERS The lawsuit is [---] pages Filed in the US District Court for the District of Delaware It is a patent-only lawsuit; Novo is NOT suing for trademark or advertising issues The patent at issue is U.S. Patent No. [-------] ('343 patent) -- Novo's"
X Link 2026-02-09T22:47Z [----] followers, [---] engagements
"$HIMS $HIMS Adjustment on Growth toward 2030🧵 Not Financial Advice FY2025: Revenue: $2.35B or 58% YoY (weightloss $740) Core $1.61B FY2026: Revenue $3.2B(36%) where weightloss may be down by 10-15% or flat. FY2027: Revenue $4.16B(30%) FY2028: Revenue: $5.2B(25%) FY2029 https://t.co/1vwVhdRONz $HIMS Adjustment on Growth toward 2030🧵 Not Financial Advice FY2025: Revenue: $2.35B or 58% YoY (weightloss $740) Core $1.61B FY2026: Revenue $3.2B(36%) where weightloss may be down by 10-15% or flat. FY2027: Revenue $4.16B(30%) FY2028: Revenue: $5.2B(25%) FY2029 https://t.co/1vwVhdRONz"
X Link 2026-02-09T22:49Z [----] followers, [---] engagements
"$HIMS $LLY $NVO $HIMS partner sues Eli Lilly and Novo Nordisk. DAMNING for Big Pharma $LLY and $NVO. The time is now. Today is the day we start to apply MAXIMUM pressure to our congressmen and women in a stern but THOUGHTFUL manner. I will posst more information in a bit after I get off a few https://t.co/ksRz62lB2a $HIMS partner sues Eli Lilly and Novo Nordisk. DAMNING for Big Pharma $LLY and $NVO. The time is now. Today is the day we start to apply MAXIMUM pressure to our congressmen and women in a stern but THOUGHTFUL manner. I will posst more information in a bit after I get off a few"
X Link 2026-02-09T22:49Z [----] followers, [---] engagements
"$HIMS $NVO $HIMS extends losses to 22% after $NVO said it is suing over knockoff obesity drugs. This comes as the FDA signals full enforcement on compounded GLP 1s and the company exits compounded semaglutide. https://t.co/1WKROCRbtU $HIMS extends losses to 22% after $NVO said it is suing over knockoff obesity drugs. This comes as the FDA signals full enforcement on compounded GLP 1s and the company exits compounded semaglutide. https://t.co/1WKROCRbtU"
X Link 2026-02-09T22:50Z [----] followers, [---] engagements
"$NWBO Three days ago $NWBO filled a Head of Patient Experience role in the UK. Interesting job title given how far along we are in the approval process. This is a launch readiness function and that signals preparation for patient rollout to me. https://t.co/YluDloIwSB Three days ago $NWBO filled a Head of Patient Experience role in the UK. Interesting job title given how far along we are in the approval process. This is a launch readiness function and that signals preparation for patient rollout to me. https://t.co/YluDloIwSB"
X Link 2026-02-09T22:50Z [----] followers, [---] engagements
"$LLY Eli Lilly $LLY to buy Orna Therapeutics (private) for $2.4 billion. Circular RNA CAR-T therapies. https://t.co/6iPghcwUuM via @matthewherper Eli Lilly $LLY to buy Orna Therapeutics (private) for $2.4 billion. Circular RNA CAR-T therapies. https://t.co/6iPghcwUuM via @matthewherper"
X Link 2026-02-09T22:50Z [----] followers, [--] engagements
"$HIMS @AndrewDudum This is EXACTLY the opposite of what you wanted to see from $HIMS management this morning I am beginning to think that @AndrewDudum has some sort of main-character narcissism flaw. I expected the ORAL PILL take-down to be a sign of them trying to make a mea culpa but this is https://t.co/67at1JNg8E This is EXACTLY the opposite of what you wanted to see from $HIMS management this morning I am beginning to think that @AndrewDudum has some sort of main-character narcissism flaw. I expected the ORAL PILL take-down to be a sign of them trying to make a mea culpa but this is"
X Link 2026-02-09T22:51Z [----] followers, [---] engagements
"$HIMS $HIMS When the Dept of treasury increases count of stocks by 50% within one quarter (Q4 13F) then you can imagine how confident are they in the company. HIMS is their top [--] investment now in terms of dollar value with avg cost $36 https://t.co/S8LhuqN118 $HIMS When the Dept of treasury increases count of stocks by 50% within one quarter (Q4 13F) then you can imagine how confident are they in the company. HIMS is their top [--] investment now in terms of dollar value with avg cost $36 https://t.co/S8LhuqN118"
X Link 2026-02-09T22:51Z [----] followers, [---] engagements
"$HIMS $HIMS & : BTIG reiterates maintains $ Analyst weighs in on semaglutide pill withdrawal cites regulatory risk as FDA ramps up GLP-1 compounding enforcement. https://t.co/F4jTHGtuIa $HIMS & : BTIG reiterates maintains $ Analyst weighs in on semaglutide pill withdrawal cites regulatory risk as FDA ramps up GLP-1 compounding enforcement. https://t.co/F4jTHGtuIa"
X Link 2026-02-09T22:52Z [----] followers, [---] engagements
"$HIMS $HIMS https://t.co/kn4ItGeV2m $HIMS https://t.co/kn4ItGeV2m"
X Link 2026-02-09T22:52Z [----] followers, [---] engagements
"$HIMS #App $HIMS App downloads are surging post superbowl ad. jumped to #5 most downloaded on the App Store. It was #22 yesterday. This is huge. https://t.co/hexPfKxEj5 $HIMS App downloads are surging post superbowl ad. jumped to #5 most downloaded on the App Store. It was #22 yesterday. This is huge. https://t.co/hexPfKxEj5"
X Link 2026-02-09T22:53Z [----] followers, [---] engagements
"$HIMS #GLP1s 🚨 BREAKING: $HIMS IS NOW OFFERING 20% OFF ON ORDERS OF $500+ Promo includes GLP-1s which brings price to $159/mo - the lowest we've seen in a while maybe ever Hims just kicked off this text message campaign with GLP-1 photo: https://t.co/AB1CQOXqzR 🚨 BREAKING: $HIMS IS NOW OFFERING 20% OFF ON ORDERS OF $500+ Promo includes GLP-1s which brings price to $159/mo - the lowest we've seen in a while maybe ever Hims just kicked off this text message campaign with GLP-1 photo: https://t.co/AB1CQOXqzR"
X Link 2026-02-09T22:54Z [----] followers, [---] engagements
"$HIMS Jeff Bezos says that if you have a 10% chance of making a 100x you should take that bet every single time. This is the case with $HIMS. Down 75% from its highs $4B market cap and a P/S ratio below [--]. $HIMS trades as if its destined to fail all the pessimism is already https://t.co/U7eCnL3Dpb Jeff Bezos says that if you have a 10% chance of making a 100x you should take that bet every single time. This is the case with $HIMS. Down 75% from its highs $4B market cap and a P/S ratio below [--]. $HIMS trades as if its destined to fail all the pessimism is already https://t.co/U7eCnL3Dpb"
X Link 2026-02-09T22:55Z [----] followers, [---] engagements
"$NVO 🚨BREAKING: $NVO THEY ACTUALLY DID IT. Novo Nordisk is asking the court to permanently ban $HIMS from selling unapproved compounded drugs that infringe our patents and is seeking to recover damages https://t.co/gvDJsOx1OT 🚨BREAKING: $NVO THEY ACTUALLY DID IT. Novo Nordisk is asking the court to permanently ban $HIMS from selling unapproved compounded drugs that infringe our patents and is seeking to recover damages https://t.co/gvDJsOx1OT"
X Link 2026-02-09T22:55Z [----] followers, [--] engagements
"$NVO $HIMS BREAKING: Novo Nordisk $NVO sues Hims & Hers $HIMS for infringing on a key Wegovy patent https://t.co/44Ndx293d4 via @pharmalot BREAKING: Novo Nordisk $NVO sues Hims & Hers $HIMS for infringing on a key Wegovy patent https://t.co/44Ndx293d4 via @pharmalot"
X Link 2026-02-09T22:56Z [----] followers, [---] engagements
"$NVO $HIMS $NVO sues $HIMS over cheaper copycat versions of Wegovy pill injections - CNBC. Stock down 20% pre-market. $18.42 - The same price as it was back in [----]. https://t.co/MuGyasfd2T $NVO sues $HIMS over cheaper copycat versions of Wegovy pill injections - CNBC. Stock down 20% pre-market. $18.42 - The same price as it was back in [----]. https://t.co/MuGyasfd2T"
X Link 2026-02-09T22:57Z [----] followers, [---] engagements
"$HIMS 🚨 BREAKING: $HIMS RESPONDS TO NOVO LAWSUIT "Big Pharma is weaponizing the US judicial system to limit consumer choice" "This lawsuit attacks more than just one medication or company it directly assaults a well-established vital component of US pharmacy practice" https://t.co/NQThXxLVJi 🚨 BREAKING: $HIMS RESPONDS TO NOVO LAWSUIT "Big Pharma is weaponizing the US judicial system to limit consumer choice" "This lawsuit attacks more than just one medication or company it directly assaults a well-established vital component of US pharmacy practice" https://t.co/NQThXxLVJi"
X Link 2026-02-09T22:58Z [----] followers, [---] engagements
"$HIMS $HIMS buy companies that look like this https://t.co/KB6bQn6QrX $HIMS buy companies that look like this https://t.co/KB6bQn6QrX"
X Link 2026-02-09T22:59Z [----] followers, [---] engagements
"$IBRX #ImmunityBio"
X Link 2026-02-09T23:00Z [----] followers, [---] engagements
"$NVO #FDA 🚨BREAKING - $NVO. The FDA flags Novo Nordisk for misleading Wegovy ad The FDA says that the ad misbrands Wegovy Semaglutide tablets and violates the Federal Food Drug and Cosmetic Act The FDA is really busy 😄 https://t.co/amH7Nko5Uq 🚨BREAKING - $NVO. The FDA flags Novo Nordisk for misleading Wegovy ad The FDA says that the ad misbrands Wegovy Semaglutide tablets and violates the Federal Food Drug and Cosmetic Act The FDA is really busy 😄 https://t.co/amH7Nko5Uq"
X Link 2026-02-09T23:01Z [----] followers, [---] engagements
"$NVO $HIMS 🚨 NOVO NORDISK HAS SUED $HIMS FOR INFRINGING ON U.S. PATENT [-------] The '343 patent is Novo's "crown jewel" patent This patent has already withstood an IRP patent challenge by Mylan Pharmaceuticals in [----] Novo is seeking both a permanent ban AND damages If a court 🚨 NOVO NORDISK HAS SUED $HIMS FOR INFRINGING ON U.S. PATENT [-------] The '343 patent is Novo's "crown jewel" patent This patent has already withstood an IRP patent challenge by Mylan Pharmaceuticals in [----] Novo is seeking both a permanent ban AND damages If a court"
X Link 2026-02-09T23:02Z [----] followers, [---] engagements
"$HIMS Once again misleading his followers. In the first half of [----] alone $HIMS generated $420M in GLP-1 revenue. We dont know the Q3 number because the company stopped reporting it but the vast majority of weight-loss revenue does come from GLP-1s. Source: Q2 10-Q filing https://t.co/ccli69DGT3 Once again misleading his followers. In the first half of [----] alone $HIMS generated $420M in GLP-1 revenue. We dont know the Q3 number because the company stopped reporting it but the vast majority of weight-loss revenue does come from GLP-1s. Source: Q2 10-Q filing https://t.co/ccli69DGT3"
X Link 2026-02-09T23:02Z [----] followers, [---] engagements
"$HIMS Interesting $HIMS https://t.co/Rixi46jzp5 Interesting $HIMS https://t.co/Rixi46jzp5"
X Link 2026-02-09T23:03Z [----] followers, [---] engagements
"$NVO $HIMS Former FDA Commissioner Scott Gottlieb on CNBC was blunt about the $NVO vs. $HIMS fight: Mass compounding of GLP-1s was meant as a temporary workaround for shortages not a permanent business model. He warned that using compounding to copy patented drugs undermines FDA Former FDA Commissioner Scott Gottlieb on CNBC was blunt about the $NVO vs. $HIMS fight: Mass compounding of GLP-1s was meant as a temporary workaround for shortages not a permanent business model. He warned that using compounding to copy patented drugs undermines FDA"
X Link 2026-02-09T23:05Z [----] followers, [---] engagements
"$HIMS IMO $HIMS entire GLP-1 operation is about to come down. $HIMS may backing off of the GLP-1 pill now but they opened Pandoras Box here coaxing the FDA into FINALLY cracking down on the overall GLP-1 mass compounding scam that $HIMS has been conducting/profiting from. https://t.co/QQKZm4Fslk IMO $HIMS entire GLP-1 operation is about to come down. $HIMS may backing off of the GLP-1 pill now but they opened Pandoras Box here coaxing the FDA into FINALLY cracking down on the overall GLP-1 mass compounding scam that $HIMS has been conducting/profiting from. https://t.co/QQKZm4Fslk"
X Link 2026-02-09T23:06Z [----] followers, [---] engagements
"$NWBO $NWBO Why did Roger Perlmutter's Eikon Therapeutics run trials on tough targets (advanced solid tumors) The combination of checking point inhibitors with TLR7/8 agonist or PARP1 inhibitor is not going to work on advanced solid tumors. We can see that two trials were marked as https://t.co/qPpt5YtoX1 $NWBO Why did Roger Perlmutter's Eikon Therapeutics run trials on tough targets (advanced solid tumors) The combination of checking point inhibitors with TLR7/8 agonist or PARP1 inhibitor is not going to work on advanced solid tumors. We can see that two trials were marked as"
X Link 2026-02-09T23:07Z [----] followers, [---] engagements
"$HIMS 🚨 BREAKING: FDA WARNED $HIMS 503B FACILITY MEDISOURCERX AFTER FINDING BUGS AND FAILING TO REPORT ADVERSE EVENT - Warning issued late [----] - In Jan [----] patient reported "severe" stomach issues from GLP-1 spent [--] nights in a hospital - Event not reported to the FDA w/in [--] https://t.co/yR8YhJlpBH 🚨 BREAKING: FDA WARNED $HIMS 503B FACILITY MEDISOURCERX AFTER FINDING BUGS AND FAILING TO REPORT ADVERSE EVENT - Warning issued late [----] - In Jan [----] patient reported "severe" stomach issues from GLP-1 spent [--] nights in a hospital - Event not reported to the FDA w/in 15"
X Link 2026-02-09T23:54Z [----] followers, [---] engagements
"$NVO $NVO - Details on the share repurchase program. Novo wil repurchase up to 3.8B DKK (about 500M) shares in the period between the 4th of February and the 4th of March. This is part of the 15B DKK program (about 1% of total market cap and worth about 2B) that will be https://t.co/oqVC8ZMrFY $NVO - Details on the share repurchase program. Novo wil repurchase up to 3.8B DKK (about 500M) shares in the period between the 4th of February and the 4th of March. This is part of the 15B DKK program (about 1% of total market cap and worth about 2B) that will be https://t.co/oqVC8ZMrFY"
X Link 2026-02-09T23:55Z [----] followers, [---] engagements
"$HIMS Caesar Capital increased its position in Hims & Hers Health $HIMS today at $17.04 per share 🏛 New average cost basis: $25.77 (down from $26.10) https://t.co/JFQlQwV4ig Caesar Capital increased its position in Hims & Hers Health $HIMS today at $17.04 per share 🏛 New average cost basis: $25.77 (down from $26.10) https://t.co/JFQlQwV4ig"
X Link 2026-02-09T23:56Z [----] followers, [---] engagements
"$IBRX $IBRX REMINDER - ImmunityBio will participate in the three-day [----] ASCO Genitourinary Cancers Symposium on February [--] - [--] at the Moscone West in San Francisco California. Held annually the event focuses on the latest research and treatments for cancers including prostate $IBRX REMINDER - ImmunityBio will participate in the three-day [----] ASCO Genitourinary Cancers Symposium on February [--] - [--] at the Moscone West in San Francisco California. Held annually the event focuses on the latest research and treatments for cancers including prostate"
X Link 2026-02-10T22:19Z [----] followers, [---] engagements
"$IBRX $IBRX right now you can buy this company that will be worth over a trillion dollars soon (within [--] years) for only $6.83B. Knowing full well how massive GLP-1s have been for obesity treatment I firmly believe that $IBRX's IL-15s broad spectrum anti-cancer peptide will become a https://t.co/ReOLBADeyG $IBRX right now you can buy this company that will be worth over a trillion dollars soon (within [--] years) for only $6.83B. Knowing full well how massive GLP-1s have been for obesity treatment I firmly believe that $IBRX's IL-15s broad spectrum anti-cancer peptide will become a"
X Link 2026-02-10T22:40Z [----] followers, [---] engagements
"$UNH $UNH Superinvestors should file remaining 13Fs by Monday 16th. I expect to see some large buys in UnitedHealth Group last quarter especially from Berkshire Hathaway-Warren Buffett. This is the same group of buyers that helped push the stock up more than 15% in Q3 after https://t.co/uh33Wr2MJZ $UNH Superinvestors should file remaining 13Fs by Monday 16th. I expect to see some large buys in UnitedHealth Group last quarter especially from Berkshire Hathaway-Warren Buffett. This is the same group of buyers that helped push the stock up more than 15% in Q3 after https://t.co/uh33Wr2MJZ"
X Link 2026-02-10T23:54Z [----] followers, [---] engagements
"$OSCR This $OSCR Guidance is INSANE 📈 - $19B Revenues +48% above estimates - $250-450M EBIT vs $5M estimate 50-100x Mark Bertolini is making a huge promise but most don't trust him. Those who do could be rewarded https://t.co/VWcnaj0Dhd This $OSCR Guidance is INSANE 📈 - $19B Revenues +48% above estimates - $250-450M EBIT vs $5M estimate 50-100x Mark Bertolini is making a huge promise but most don't trust him. Those who do could be rewarded https://t.co/VWcnaj0Dhd"
X Link 2026-02-10T23:54Z [----] followers, [---] engagements
"$OSCR 🦉 Oscar put in place a $475M secured revolver maturing in [----]. The facility carries SOFR-linked pricing and quarterly covenants tied to premiums EBITDA liquidity and leverage. #form_8K"
X Link 2026-02-11T00:14Z [----] followers, [---] engagements
"$IBRX @DrPatrick How does $IBRX benefit from the Saudi FDA approval of Anktiva What say the fanboys/girls of @DrPatrick on this question I'm not talking about the stock price so spare me that reply. What material benefit will ImmunityBio gain from focusing on Saudi Arabia How does $IBRX benefit from the Saudi FDA approval of Anktiva What say the fanboys/girls of @DrPatrick on this question I'm not talking about the stock price so spare me that reply. What material benefit will ImmunityBio gain from focusing on Saudi Arabia"
X Link 2026-02-11T17:20Z [----] followers, [---] engagements
"$UNH Hedge funds are heavily overweight healthcare stocks. For reference $UNH was the most bought stock by hedge funds in Q3 [----]. The sector is now valued at just 18x forward earnings against 22x of S&P [---]. Long healthcare. $UNH $OSCR $CNC $CI $MOH $ELV https://t.co/R16TYkEpiM Hedge funds are heavily overweight healthcare stocks. For reference $UNH was the most bought stock by hedge funds in Q3 [----]. The sector is now valued at just 18x forward earnings against 22x of S&P [---]. Long healthcare. $UNH $OSCR $CNC $CI $MOH $ELV https://t.co/R16TYkEpiM"
X Link 2026-02-11T17:51Z [----] followers, [---] engagements
"$IBRX $IBRX 🚨🤯🚨 OMG Everyone must see this Current free float is [---] million shares short interest is [---] million shares That means over the stock run up shorts have increased their shorting and right now there's more shorts than shares in free float We are set up for most https://t.co/2YYApSmBNe $IBRX 🚨🤯🚨 OMG Everyone must see this Current free float is [---] million shares short interest is [---] million shares That means over the stock run up shorts have increased their shorting and right now there's more shorts than shares in free float We are set up for most https://t.co/2YYApSmBNe"
X Link 2026-02-11T17:52Z [----] followers, [---] engagements
"$NVO $LLY Motley Fool says there are [--] healthcare stocks to buy on the dip and $NVO is one of them. Their take: Novo is now second fiddle to $LLY. Lillys Mounjaro +99% sales growth Zepbound +175% Novos obesity portfolio +31% They argue pricing pressure in the U.S. will Motley Fool says there are [--] healthcare stocks to buy on the dip and $NVO is one of them. Their take: Novo is now second fiddle to $LLY. Lillys Mounjaro +99% sales growth Zepbound +175% Novos obesity portfolio +31% They argue pricing pressure in the U.S. will"
X Link 2026-02-11T17:54Z [----] followers, [---] engagements
"$OSCR $OSCR guided for [---] million members but 400K of those are expected to drop off by end of Q1. They were $0 premium enrollees who got passively renewed into plans that now cost actual money. They're in a grace period through March. If they don't pay they're off the books. So https://t.co/SLkYw0Qp3L $OSCR guided for [---] million members but 400K of those are expected to drop off by end of Q1. They were $0 premium enrollees who got passively renewed into plans that now cost actual money. They're in a grace period through March. If they don't pay they're off the books. So"
X Link 2026-02-11T17:54Z [----] followers, [---] engagements
"$IBRX 🚀 $IBRX [----] Catalyst Rocket: FDA Resub INCOMING ASCO GU Buzz Saudi Rollout Heating Up Earnings Beat Potential Major BLA Path & Global Expansion This Dip Is Pure Setup for Explosive Leg Up 💥 Todays dip stings after that breakout pure profit-taking + volatility no https://t.co/3w7ouusihX 🚀 $IBRX [----] Catalyst Rocket: FDA Resub INCOMING ASCO GU Buzz Saudi Rollout Heating Up Earnings Beat Potential Major BLA Path & Global Expansion This Dip Is Pure Setup for Explosive Leg Up 💥 Todays dip stings after that breakout pure profit-taking + volatility no https://t.co/3w7ouusihX"
X Link 2026-02-11T17:55Z [----] followers, [---] engagements
"$NWBO $NWBO has solved the mass production problem with #Eden #DCVax 🔥 $NWBO has solved the mass production problem with #Eden #DCVax 🔥"
X Link 2026-02-11T17:55Z [----] followers, [---] engagements
"$NWBO #DCVax 🧠 $NWBO #DCVax and the #Treg Blueprint: Why Durability Is a State Not a Schedule Wardell Boardman and Levings (Nat Rev Drug Discov 2025) make a clean point: regulatory T cells are not anti-inflammatory vibes. They are the immune systems control layer. They enforce https://t.co/Hrura93IUA 🧠 $NWBO #DCVax and the #Treg Blueprint: Why Durability Is a State Not a Schedule Wardell Boardman and Levings (Nat Rev Drug Discov 2025) make a clean point: regulatory T cells are not anti-inflammatory vibes. They are the immune systems control layer. They enforce https://t.co/Hrura93IUA"
X Link 2026-02-11T17:56Z [----] followers, [---] engagements
"$OSCR #Oscar Here are a few highlights from Oscars latest earnings call as reported this week. 👉 FY25 revenue: Increased to approximately $11.7B up 28% year-over-year 👉 FY25 SG&A expense ratio: 17.5% improved approximately [---] basis points year-over-year In addition as of February https://t.co/Ut5QTUpGqy Here are a few highlights from Oscars latest earnings call as reported this week. 👉 FY25 revenue: Increased to approximately $11.7B up 28% year-over-year 👉 FY25 SG&A expense ratio: 17.5% improved approximately [---] basis points year-over-year In addition as of February"
X Link 2026-02-11T17:58Z [----] followers, [---] engagements
"$IBRX @DrPatrick Dr. Patrick Soon-Shiong just exposed a maddening FDA reality on his own approved cancer drug (Anktiva): Its fully approved in the US for one rare form of bladder cancer but not for the common form most patients have. So even though the same drug is already FDA-approved and https://t.co/jb46zpPbPL Dr. Patrick Soon-Shiong just exposed a maddening FDA reality on his own approved cancer drug (Anktiva): Its fully approved in the US for one rare form of bladder cancer but not for the common form most patients have. So even though the same drug is already FDA-approved and"
X Link 2026-02-12T19:01Z [----] followers, [---] engagements
"$IBRX @ImmunityBio"
X Link 2026-02-12T19:02Z [----] followers, [---] engagements
"$IBRX $IBRX - Feb 11th [----] Short Data Analysis based on real data . 1- Utilization is now 100%. What does that mean What Does "100% Utilization" Mean Think of the stock market like a car rental lot. 100% Utilization means every single car (share) available for rent (shorting) https://t.co/Gj6iCRwccP $IBRX - Feb 11th [----] Short Data Analysis based on real data . 1- Utilization is now 100%. What does that mean What Does "100% Utilization" Mean Think of the stock market like a car rental lot. 100% Utilization means every single car (share) available for rent (shorting) https://t.co/Gj6iCRwccP"
X Link 2026-02-12T19:03Z [----] followers, [---] engagements
"$PEPG #PepGen $pepg up 50% in [--] trading days. Data ANY day now. https://t.co/gh6IgYfpPa $pepg up 50% in [--] trading days. Data ANY day now. https://t.co/gh6IgYfpPa"
X Link 2026-02-12T19:04Z [----] followers, [--] engagements
"$IBRX #Anktiva $MRK FDA encouraged Merck to proceed based on breakthrough therapy designation. Anktiva has Breakthrough Therapy Designation (BTD). Priority review was denied in [----] when BLA was filed despite BTD. Now Anktiva has RMAT status and Expanded Access Authorization across multiple tumor https://t.co/YgYY5nsx3r FDA encouraged Merck to proceed based on breakthrough therapy designation. Anktiva has Breakthrough Therapy Designation (BTD). Priority review was denied in [----] when BLA was filed despite BTD. Now Anktiva has RMAT status and Expanded Access Authorization across multiple tumor"
X Link 2026-02-12T19:06Z [----] followers, [---] engagements
"$UNH $UNH UnitedHealth Group is going to do very well on earnings this year which should shock the market at a $250 Billion MC Exactly what $META MC was at when it was trading near the $90s. MA Increase % this year is nearly 7.5% including all factors which is huge. Deep Value. https://t.co/1CGvz31jhl $UNH UnitedHealth Group is going to do very well on earnings this year which should shock the market at a $250 Billion MC Exactly what $META MC was at when it was trading near the $90s. MA Increase % this year is nearly 7.5% including all factors which is huge. Deep Value. https://t.co/1CGvz31jhl"
X Link 2026-02-12T19:07Z [----] followers, [---] engagements
"$IBRX $IBRX shorts got PLAYED. They piled in heavy on insider FDA dirtbetting on papillary rejection/delays thinking ANKTIVA was dead in the water. Then Dr. Pat drops the HAMMER: Saudi FDA slams accelerated approvals for ANKTIVA in BLADDER AND NSCLC first worldwide subQ IL-15 wins $IBRX shorts got PLAYED. They piled in heavy on insider FDA dirtbetting on papillary rejection/delays thinking ANKTIVA was dead in the water. Then Dr. Pat drops the HAMMER: Saudi FDA slams accelerated approvals for ANKTIVA in BLADDER AND NSCLC first worldwide subQ IL-15 wins"
X Link 2026-02-12T19:07Z [----] followers, [---] engagements
"$UNH Mizuho cut its price recommendation on $UNH to $350 from $430 but kept an Outperform rating on the stock. The revision came after the companys Q4 results with the firm pointing to a slower-than-expected earnings recovery as the main reason for the https://t.co/ooKxI9ImgP Mizuho cut its price recommendation on $UNH to $350 from $430 but kept an Outperform rating on the stock. The revision came after the companys Q4 results with the firm pointing to a slower-than-expected earnings recovery as the main reason for the https://t.co/ooKxI9ImgP"
X Link 2026-02-12T19:08Z [----] followers, [---] engagements
"$IBRX $IBRX Call volume 📈 "Financial giants have made a bullish move on ImmunityBio. Our analysis of options history reveal 57% of traders were bullish while 26% showed bearish tendencies." - @Benzinga Trades spotted: [--] puts valued at $71500 [--] calls valued at $1230478 https://t.co/7hnFH8nCXK $IBRX Call volume 📈 "Financial giants have made a bullish move on ImmunityBio. Our analysis of options history reveal 57% of traders were bullish while 26% showed bearish tendencies." - @Benzinga Trades spotted: [--] puts valued at $71500 [--] calls valued at $1230478 https://t.co/7hnFH8nCXK"
X Link 2026-02-12T19:08Z [----] followers, [---] engagements
"$IBRX @DrPatrick @ImmunityBio #ImmunityBio doesn't just deliver a drug; it utilizes second-generation adenovirus (hAd5) vector technology to transform our bodies into a "special forces unit" for hunting viruses. The company uses adenoviruses genetically modified to be harmless to humans as a type of #ImmunityBio doesn't just deliver a drug; it utilizes second-generation adenovirus (hAd5) vector technology to transform our bodies into a "special forces unit" for hunting viruses. The company uses adenoviruses genetically modified to be harmless to humans as a type of"
X Link 2026-02-12T19:10Z [----] followers, [---] engagements
"$NVO $HIMS $NVO CEO Mike Doustdar to compounders: time to partner not copy. Despite suing 130+ copycat sellers (incl. $HIMS) he says many built patient access Novo couldnt reach. Example: Ro now sells the branded drug and became a very good partner. But nothing in his comments $NVO CEO Mike Doustdar to compounders: time to partner not copy. Despite suing 130+ copycat sellers (incl. $HIMS) he says many built patient access Novo couldnt reach. Example: Ro now sells the branded drug and became a very good partner. But nothing in his comments"
X Link 2026-02-12T19:11Z [----] followers, [---] engagements
"$OSCR #Oscar As we shared with our full-year [----] results and [----] outlook Oscars vision remains clear: were leading the individual market with a consumer-first experience member-focused tools powered by AI and a clear path back to profitability. Read our full earnings release here: https://t.co/Ev1o5QtLFD As we shared with our full-year [----] results and [----] outlook Oscars vision remains clear: were leading the individual market with a consumer-first experience member-focused tools powered by AI and a clear path back to profitability. Read our full earnings release here:"
X Link 2026-02-12T19:12Z [----] followers, [---] engagements
"$VKTX $VKTX excellent execution i I take $VKTX CEO any day his execution has been spectacular in getting these trials up and running and FDA blessings done VANQUISH-1: Enrollment complete [----] patients (exceeded target) - VANQUISH-2: Nearing full enrollment in 1Q26 - Oral VK2735: $VKTX excellent execution i I take $VKTX CEO any day his execution has been spectacular in getting these trials up and running and FDA blessings done VANQUISH-1: Enrollment complete [----] patients (exceeded target) - VANQUISH-2: Nearing full enrollment in 1Q26 - Oral VK2735:"
X Link 2026-02-12T19:13Z [----] followers, [---] engagements
"$SNY $XBI 🚨WOW @Sanofi's CEO was just ousted The companys board of directors met on February [--] [----] and decided not to renew the Director mandate of Paul Hudson As a result Paul Hudsons last day as $SNY CEO will be on February [--] [----] at the end of business. The board has https://t.co/blC4H7PjhG 🚨WOW @Sanofi's CEO was just ousted The companys board of directors met on February [--] [----] and decided not to renew the Director mandate of Paul Hudson As a result Paul Hudsons last day as $SNY CEO will be on February [--] [----] at the end of business. The board has https://t.co/blC4H7PjhG"
X Link 2026-02-12T19:27Z [----] followers, [---] engagements
"$IBRX $IBRX is actively advancing clinical research in glioblastoma an aggressive Grade [--] brain tumor with limited treatment options and median survival typically just over one year post-diagnosis. Full focus on Innovative immunotherapy combinations in ongoing Ph [--] trial $IBRX is actively advancing clinical research in glioblastoma an aggressive Grade [--] brain tumor with limited treatment options and median survival typically just over one year post-diagnosis. Full focus on Innovative immunotherapy combinations in ongoing Ph [--] trial"
X Link 2026-02-12T19:28Z [----] followers, [---] engagements
"$IBRX #ImmunityBio $MRK #ANKTIVA #ImmunityBio has saved patients who had failed even Keytruda the world's number one cancer drug. In recently released lung cancer data patients achieved a median overall survival of [----] monthsstretching up to [----] monthswhich is more than double the [--] to [--] months seen with #ImmunityBio has saved patients who had failed even Keytruda the world's number one cancer drug. In recently released lung cancer data patients achieved a median overall survival of [----] monthsstretching up to [----] monthswhich is more than double the [--] to [--] months seen with"
X Link 2026-02-12T19:29Z [----] followers, [---] engagements
"$VKTX $VKTX Huge news for shareholders- Boom Oral drug moving to Ph3 guys https://t.co/DHczsATn4F $VKTX Huge news for shareholders- Boom Oral drug moving to Ph3 guys https://t.co/DHczsATn4F"
X Link 2026-02-12T19:30Z [----] followers, [---] engagements
"$NVO #Wegovy $NVO oral version of Wegovy (semaglutide) launched in January has seen significant uptake with approximately 36% of users being new to GLP-1 therapies. A study by Truveta reveals that 21% of users transitioned from the injectable Wegovy while 16% came from $LLY Zepbound https://t.co/VIP0XF8vj8 $NVO oral version of Wegovy (semaglutide) launched in January has seen significant uptake with approximately 36% of users being new to GLP-1 therapies. A study by Truveta reveals that 21% of users transitioned from the injectable Wegovy while 16% came from $LLY Zepbound"
X Link 2026-02-12T19:31Z [----] followers, [---] engagements
"$VKTX $VKTX new slides & nice pic from piper that sums it up well on catalysts https://t.co/DmzAtMVv8P https://t.co/79HABADM4h $VKTX new slides & nice pic from piper that sums it up well on catalysts https://t.co/DmzAtMVv8P https://t.co/79HABADM4h"
X Link 2026-02-12T19:35Z [----] followers, [---] engagements
"$VKTX $VKTX Stifel $VKTX remains undeterred by expanding competition in the obesity landscape. Notably VKTX is aligning its programs with next- generation profiles that not only address tolerability but issues with treatment duration exploring both weeklymonthly and weeklyoral $VKTX Stifel $VKTX remains undeterred by expanding competition in the obesity landscape. Notably VKTX is aligning its programs with next- generation profiles that not only address tolerability but issues with treatment duration exploring both weeklymonthly and weeklyoral"
X Link 2026-02-12T19:37Z [----] followers, [---] engagements
"$NKTR 🦉 Nektar raised $400M at $58 a share in an upsized equity sale issuing 6.6M shares and pre-funded warrants. The company turns to the market before Phase [--] rezpegaldesleukin costs escalate tapping its November [----] shelf to secure fresh cash. https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-announces-pricing-upsized-400-million-public https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-announces-pricing-upsized-400-million-public"
X Link 2026-02-12T19:42Z [----] followers, [---] engagements
"$ZYME 🦉 Zymeworks will report Q4 and full-year [----] results pre-market March [--] with a call at 8:30 a.m. ET. The company has yet to publish year-end figures leaving updated cash revenue and pipeline data pending. https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-report-fourth-quarter-and-full-year-2025-financial https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-report-fourth-quarter-and-full-year-2025-financial"
X Link 2026-02-12T19:47Z [----] followers, [--] engagements
"$CGEN 🦉 Compugen appointed Michele Holcomb to its board as an independent director effective Feb. [--]. The addition comes as the company remains clinical-stage reliant on partnered programs and without approved products generating revenue. https://cgen.com/investors-and-media/press-releases/news-details/2026/Compugen-Announces-the-Appointment-of-Michele-Holcomb-Ph-D--to-its-Board-of-Directors/default.aspx https://cgen.com/investors-and-media/press-releases/news-details/2026/Compugen-Announces-the-Appointment-of-Michele-Holcomb-Ph-D--to-its-Board-of-Directors/default.aspx"
X Link 2026-02-12T19:56Z [----] followers, [--] engagements
"$BBIO 🦉 BBIO said Phase [--] PROPEL [--] met its goal; infigratinib added +1.74 cm/year vs placebo and was first to show significant body proportionality gains. No oral FGFR3 drug has done this; FDA filing talks set for 2H26."
X Link 2026-02-12T20:22Z [----] followers, [---] engagements
"$BBIO $BMRN BridgeBio $BBIO drug for genetic cause of dwarfism succeeds in key study This is the third consecutive Phase [--] success for BridgeBio. It also could spell trouble for $BMRN's competing dwarfism drug. https://t.co/mwnbVetPFy via @damiangarde BridgeBio $BBIO drug for genetic cause of dwarfism succeeds in key study This is the third consecutive Phase [--] success for BridgeBio. It also could spell trouble for $BMRN's competing dwarfism drug. https://t.co/mwnbVetPFy via @damiangarde"
X Link 2026-02-12T20:23Z [----] followers, [---] engagements
"$HIMS $LLY $NVO $HIMS $LLY $NVO 🚨 FOUNDER & CEO OF MOCHI HEALTH: EXPECT "WAY HIGHER" CHURN ON NOVO'S GLP-1 PILL " The orals just don't work very well. Rybelsus has been on the market for years. And nobody takes it" " I think the pill is a great on-ramp but it also just doesn't really https://t.co/wVjd6ByJIX $HIMS $LLY $NVO 🚨 FOUNDER & CEO OF MOCHI HEALTH: EXPECT "WAY HIGHER" CHURN ON NOVO'S GLP-1 PILL " The orals just don't work very well. Rybelsus has been on the market for years. And nobody takes it" " I think the pill is a great on-ramp but it also just doesn't really"
X Link 2026-02-12T20:23Z [----] followers, [---] engagements
"$HIMS $LLY $NVO $HIMS $LLY $NVO 🚨 SABINA HEMMI (@LAWLIEPOP) ON THE FDA's GLP-1 ANNOUNCEMENT LAST FRIDAY: "It's clearly been sparked by Hims's actions." "While the most concerning part of the FDA statement is its mention of API's it seems to primarily be focused on marketing. They directly https://t.co/VJ0ufiWvNR $HIMS $LLY $NVO 🚨 SABINA HEMMI (@LAWLIEPOP) ON THE FDA's GLP-1 ANNOUNCEMENT LAST FRIDAY: "It's clearly been sparked by Hims's actions." "While the most concerning part of the FDA statement is its mention of API's it seems to primarily be focused on marketing. They directly"
X Link 2026-02-12T20:44Z [----] followers, [---] engagements
"$VKTX $VKTX in less then [--] months $VKTX completed enrollment on both its PHASE [--] trials for SUBq - enrollment rates as fast $LLY $VKTX in less then [--] months $VKTX completed enrollment on both its PHASE [--] trials for SUBq - enrollment rates as fast $LLY"
X Link 2026-02-12T20:44Z [----] followers, [---] engagements
"$CRBU 🦉 Caribou Biosciences will speak at Citi and Leerink investor events; no clinical data no FDA update no capital raise disclosed. The stock had no fresh catalyst after prior CAR-T updates. https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-participate-upcoming-investor-conferences-12 https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-participate-upcoming-investor-conferences-12"
X Link 2026-02-12T21:31Z [----] followers, [---] engagements
"$HIMS $HIMS stock is down to IPO levels while revenue is up 14X since. https://t.co/YghcA4t8zc $HIMS stock is down to IPO levels while revenue is up 14X since. https://t.co/YghcA4t8zc"
X Link 2026-02-13T15:53Z [----] followers, [---] engagements
"$NVO #Wegovy 🚨BREAKING - Wegovy Pill sales are up 34% $NVO TRx came in at [------] in the 5th week after launch. Up from TRx [-----] last week. This is the IQVIA data which is widely regarded as the most trustworthy and accurate Remember this still without the effect of the Superbowl https://t.co/ewCLNIS0xG 🚨BREAKING - Wegovy Pill sales are up 34% $NVO TRx came in at [------] in the 5th week after launch. Up from TRx [-----] last week. This is the IQVIA data which is widely regarded as the most trustworthy and accurate Remember this still without the effect of the Superbowl https://t.co/ewCLNIS0xG"
X Link 2026-02-13T15:54Z [----] followers, [---] engagements
"$HIMS Wild to see that $HIMS is down 30% over the past five years https://t.co/dG3Ur6LVzD Wild to see that $HIMS is down 30% over the past five years https://t.co/dG3Ur6LVzD"
X Link 2026-02-13T15:55Z [----] followers, [---] engagements
"$NWBO #DCVax $NWBO #DCVax $GME $AMC $MMTLP @MichaelJBurry__ @TheRoaringKitty https://t.co/FJcfItT7fR $NWBO #DCVax $GME $AMC $MMTLP @MichaelJBurry__ @TheRoaringKitty https://t.co/FJcfItT7fR"
X Link 2026-02-13T15:55Z [----] followers, [---] engagements
"$HIMS $HIMS WEEKLY (Feb [--] 2026) - One of the most chaotic weeks in history 😵💫 - Stock price down -28% - Hims pulls pill - Novo lawsuit - Pressure from FDA + DOJ - Short interest at all-time high 🤯 - BTIG $60 PT Morgan Stanley $40 Citi $16.50 BofA $13 👉 https://t.co/UQ2nOKaXfl https://t.co/zbidzo9ict $HIMS WEEKLY (Feb [--] 2026) - One of the most chaotic weeks in history 😵💫 - Stock price down -28% - Hims pulls pill - Novo lawsuit - Pressure from FDA + DOJ - Short interest at all-time high 🤯 - BTIG $60 PT Morgan Stanley $40 Citi $16.50 BofA $13 👉 https://t.co/UQ2nOKaXfl"
X Link 2026-02-13T15:56Z [----] followers, [---] engagements
"$LLY $NVO $VKTX $LLY builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision. $NVO $VKTX https://t.co/7PyoEtEw5D $LLY builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision. $NVO $VKTX https://t.co/7PyoEtEw5D"
X Link 2026-02-13T15:58Z [----] followers, [---] engagements
"$NKTR $CRVS $NKTR cantor Rezpegaldesleukin (Rezpeg). The best-in-class durability provides the first clinical proof that Tregs can induce durable responses in AD patients. We see this data point as further validation for $CRVS soquelitinib (SQL) an ITK inhibitor that acts on Treg mechanism https://t.co/KRchZKpJAW $NKTR cantor Rezpegaldesleukin (Rezpeg). The best-in-class durability provides the first clinical proof that Tregs can induce durable responses in AD patients. We see this data point as further validation for $CRVS soquelitinib (SQL) an ITK inhibitor that acts on Treg mechanism"
X Link 2026-02-14T23:28Z [----] followers, [---] engagements
"$UNH $UNH is right back to its Covid Low price You can rotate from overvalued US Tech to undervalued Health today $UNH is right back to its Covid Low price You can rotate from overvalued US Tech to undervalued Health today"
X Link 2026-02-16T20:59Z [----] followers, [---] engagements
"$IBRX Elevated short interest in $IBRX has been interpreted as weakness. From a long-term institutional perspective it may instead reflect a misunderstanding of platform biotechnology during the early commercialization phase. Historically markets misprice companies transitioning Elevated short interest in $IBRX has been interpreted as weakness. From a long-term institutional perspective it may instead reflect a misunderstanding of platform biotechnology during the early commercialization phase. Historically markets misprice companies transitioning"
X Link 2026-02-16T20:57Z [----] followers, [----] engagements
"$HIMS $NVO $LLY 🚨 BREAKING: SENATOR TOM COTTON DEMANDS FDA INVESTIGATE ILLEGAL CHINESE INGREDIENTS IN COMPOUNDED GLP-1s $HIMS $NVO $LLY https://t.co/zjJhx4NYB1 🚨 BREAKING: SENATOR TOM COTTON DEMANDS FDA INVESTIGATE ILLEGAL CHINESE INGREDIENTS IN COMPOUNDED GLP-1s $HIMS $NVO $LLY https://t.co/zjJhx4NYB1"
X Link 2026-02-16T21:12Z [----] followers, [---] engagements
"$ABVX $ABVX new SVP Reg Affairs - currently already [--] reg affairs folks - regulatory execution risk reduced (FDA/EMA hurdles) - however long any deal takes they'll still need to clear their filings/submissions - to keep an eye out if they go at it alone (my hunch is no) https://t.co/4du8mgIkGO $ABVX new SVP Reg Affairs - currently already [--] reg affairs folks - regulatory execution risk reduced (FDA/EMA hurdles) - however long any deal takes they'll still need to clear their filings/submissions - to keep an eye out if they go at it alone (my hunch is no) https://t.co/4du8mgIkGO"
X Link 2026-02-16T21:21Z [----] followers, [---] engagements
"$RHHBY 🦉 Roches Gazyva beat tacrolimus in Phase [--] putting more kidney patients into full remission and opening FDA and EMA filing plans. No approved drugs exist for primary membranous nephropathy; treatment relies on repurposed immunosuppressants. https://ml-eu.globenewswire.com/Resource/Download/798907f8-adde-4c94-b0fd-89206716d75e https://ml-eu.globenewswire.com/Resource/Download/798907f8-adde-4c94-b0fd-89206716d75e"
X Link 2026-02-16T21:33Z [----] followers, [--] engagements
"$OCUL $EYPT A rival goes after Ocular Therapeutix $OCUL on eve of pivotal readout on eye treatment Eyepoint Pharma $EYPT CEO said to have trash-talked Oculars drug at a recent investor conference https://t.co/LSUm4WPWKA A rival goes after Ocular Therapeutix $OCUL on eve of pivotal readout on eye treatment Eyepoint Pharma $EYPT CEO said to have trash-talked Oculars drug at a recent investor conference https://t.co/LSUm4WPWKA"
X Link 2026-02-05T23:19Z [----] followers, [---] engagements
"$NWBO #DCVax 🧠 DCVax Is the Base Layer: Why the GBM Immunity Cycle Is Not Broken but Rerouted by Failed Combination Architecture $NWBO #DCVax (ATL-DC) #Hiltonol poly-ICLC $MRK #Keytruda pembrolizumab $BMY #Opdivo nivolumab $BMY #Yervoy ipilimumab $BMY #Opdualag nivolumab + relatlimab https://t.co/AKwxyz2VJC 🧠 DCVax Is the Base Layer: Why the GBM Immunity Cycle Is Not Broken but Rerouted by Failed Combination Architecture $NWBO #DCVax (ATL-DC) #Hiltonol poly-ICLC $MRK #Keytruda pembrolizumab $BMY #Opdivo nivolumab $BMY #Yervoy ipilimumab $BMY #Opdualag nivolumab + relatlimab"
X Link 2026-02-07T19:54Z [----] followers, [---] engagements
"$ARVN 🦉 Arvinas tapped insider Randy Teel as CEO as longtime chief John Houston steps aside stays on as adviser. The handoff comes after the companys first pivotal PROTAC readout with leadership shifting from platform building to execution. https://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-appointment-randy-teel-phd-president-chief https://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-appointment-randy-teel-phd-president-chief"
X Link 2026-02-12T19:54Z [----] followers, [---] engagements
"$BNTC 🦉 Four of four BB-301 patients met responder criteria at [--] months with one showing deeper benefit at [--] months as Benitec plans an FDA meeting to set a pivotal study mid-2026. The program remains early-stage Cohort [--] data due mid-2026. https://www.benitec.com/for-investors/news-events/press-releases/detail/142/benitec-biopharma-releases-second-quarter-2026-financial-results-and-provides-operational-update https://www.benitec.com/for-investors/news-events/press-releases/detail/142/benitec-biopharma-releases-second-quarter-2026-financial-results-and-provides-operational-update"
X Link 2026-02-12T20:40Z [----] followers, [---] engagements
"$NWBO #DCVax 🧬 Why the New Nature #mRNA Study Quietly Proves the Superiority of $NWBO #DCVax And Why mRNA Cancer Vaccines Cannot Match Dendritic-Cell Immunotherapy. and why the #FDA is correct. 🔗https://t.co/v451mF4xqH https://t.co/bxycWLb7Hs 🧬 Why the New Nature #mRNA Study Quietly Proves the Superiority of $NWBO #DCVax And Why mRNA Cancer Vaccines Cannot Match Dendritic-Cell Immunotherapy. and why the #FDA is correct. 🔗https://t.co/v451mF4xqH https://t.co/bxycWLb7Hs"
X Link 2026-02-13T15:52Z [----] followers, [---] engagements
"$HIMS 🚨 $HIMS RETREAT FROM GLP-1 PILL MAY SHIELD IT FROM DOJ ACTION - Trump administration could pursue injunction or fines - Attorney James Boiani (Epstein Becker & Green) noted Hims quick retreat from the GLP-1 pill may eliminate the case or controversy needed for DOJ to act https://t.co/r7kyMYSz54 🚨 $HIMS RETREAT FROM GLP-1 PILL MAY SHIELD IT FROM DOJ ACTION - Trump administration could pursue injunction or fines - Attorney James Boiani (Epstein Becker & Green) noted Hims quick retreat from the GLP-1 pill may eliminate the case or controversy needed for DOJ to act https://t.co/r7kyMYSz54"
X Link 2026-02-13T15:53Z [----] followers, [---] engagements
"$IBRX $IBRX Blackrock ImmunityBio Second Largest Institutional Holder Increases Its Stake By 5.8mil Shares In 4Q25 ie +29% Reaching Up 25.6mil Shares Overall. https://t.co/cLFTH7p6J3 $IBRX Blackrock ImmunityBio Second Largest Institutional Holder Increases Its Stake By 5.8mil Shares In 4Q25 ie +29% Reaching Up 25.6mil Shares Overall. https://t.co/cLFTH7p6J3"
X Link 2026-02-13T15:53Z [----] followers, [---] engagements
"$NWBO $NWBO The results from DC vaccine trials conducted by Moffitt Cancer Center are already amazing. If these DC vaccine trials had nothing to do with $NWBO would the shorts promote these trials and use them to push $NWBO to the verge of bankruptcy Would the shorts spread the https://t.co/xzeWIPO4vR $NWBO The results from DC vaccine trials conducted by Moffitt Cancer Center are already amazing. If these DC vaccine trials had nothing to do with $NWBO would the shorts promote these trials and use them to push $NWBO to the verge of bankruptcy Would the shorts spread the https://t.co/xzeWIPO4vR"
X Link 2026-02-13T15:53Z [----] followers, [---] engagements
"$IBRX $IBRX- A RARE CONVERGENCE OF FUNDAMENTAL REGULATORY AND TECHNICAL TRIGGERS. Here is the unbiased data-driven information about why February [----] [----] represents a "Mega-Window" that could redefine $IBRX valuation. PART 1: THE "WHY Market volatility often feels random $IBRX- A RARE CONVERGENCE OF FUNDAMENTAL REGULATORY AND TECHNICAL TRIGGERS. Here is the unbiased data-driven information about why February [----] [----] represents a "Mega-Window" that could redefine $IBRX valuation. PART 1: THE "WHY Market volatility often feels random"
X Link 2026-02-13T15:58Z [----] followers, [---] engagements
"#ImmunityBio $IBRX #ANKTIVA #ImmunityBio is not just about a single drug; it is a platform. If $MRK dominated the oncology market with Keytruda MSI-H indication $IBRX delivers even more potent results through #ANKTIVA RMAT status. It has demonstrated a miracle by doubling the survival rate for patients #ImmunityBio is not just about a single drug; it is a platform. If $MRK dominated the oncology market with Keytruda MSI-H indication $IBRX delivers even more potent results through #ANKTIVA RMAT status. It has demonstrated a miracle by doubling the survival rate for patients"
X Link 2026-02-13T15:59Z [----] followers, [---] engagements
"$IBRX #ImmunityBio"
X Link 2026-02-13T23:10Z [----] followers, [---] engagements
"$HIMS $HIMS The market is basically pricing this as dead. A lot of people say it's going to [--]. This is the dumbest thing you can think right here. The company is profitable and growing. None of the things that happened lately really damaged the core business. Most people are just https://t.co/MUjDuS2BVX $HIMS The market is basically pricing this as dead. A lot of people say it's going to [--]. This is the dumbest thing you can think right here. The company is profitable and growing. None of the things that happened lately really damaged the core business. Most people are just"
X Link 2026-02-13T23:11Z [----] followers, [---] engagements
"$IBRX #ANKTIVA As we continue our journey with #ANKTIVA Im grateful to share that Andrew will be starting NK Cell infusions at his next visit.📊 Please see the chart youll notice a drop after Andrew had to do one week of chemo but ANKTIVA is already helping push his ALC back in the right https://t.co/N7gVWEClqy As we continue our journey with #ANKTIVA Im grateful to share that Andrew will be starting NK Cell infusions at his next visit.📊 Please see the chart youll notice a drop after Andrew had to do one week of chemo but ANKTIVA is already helping push his ALC back in the right"
X Link 2026-02-13T23:12Z [----] followers, [---] engagements
"$IBRX #ANKTIVA As we continue our journey with #ANKTIVA Im grateful to share that Andrew will be starting NK Cell infusions at his next visit.📊 Please see the chart youll notice a drop after Andrew had to do one week of chemo but ANKTIVA is already helping push his ALC back in the right https://t.co/N7gVWEClqy As we continue our journey with #ANKTIVA Im grateful to share that Andrew will be starting NK Cell infusions at his next visit.📊 Please see the chart youll notice a drop after Andrew had to do one week of chemo but ANKTIVA is already helping push his ALC back in the right"
X Link 2026-02-13T23:12Z [----] followers, [---] engagements
"$NWBO #DCVax 🧬 THE KALINSKI $NWBO #DCVax MASTER CIRCUIT Vaccines intratumoral live adjuvants DC-assisted adoptive T-cell therapy #Boolean execution and #PanCAN FcR-compatible PD-L1 stabilization with $AZN #durvalumab #IMFINZI 🔗 https://t.co/j0aFz2IT8o https://t.co/SGIYdNWC9q 🧬 THE KALINSKI $NWBO #DCVax MASTER CIRCUIT Vaccines intratumoral live adjuvants DC-assisted adoptive T-cell therapy #Boolean execution and #PanCAN FcR-compatible PD-L1 stabilization with $AZN #durvalumab #IMFINZI 🔗 https://t.co/j0aFz2IT8o https://t.co/SGIYdNWC9q"
X Link 2026-02-13T23:13Z [----] followers, [---] engagements
"$NWBO #DCVax $NWBO #DCVax #EndCancer @MHRAgovuk https://t.co/6iRajfXCpf $NWBO #DCVax #EndCancer @MHRAgovuk https://t.co/6iRajfXCpf"
X Link 2026-02-14T23:16Z [----] followers, [---] engagements
"$NWBO $NWBO Moffitt Magnolia Ball Raises Millions To Benefit Cancer Research and Treatment https://t.co/pll7dZsjtG Nearly 1000attendeesfilled the room atMoffitt Cancer Centers31st annual Magnolia Ballall sharing the samemission: to contribute to the prevention and cure of $NWBO Moffitt Magnolia Ball Raises Millions To Benefit Cancer Research and Treatment https://t.co/pll7dZsjtG Nearly 1000attendeesfilled the room atMoffitt Cancer Centers31st annual Magnolia Ballall sharing the samemission: to contribute to the prevention and cure of"
X Link 2026-02-14T23:18Z [----] followers, [---] engagements
"$NWBO $NWBO 🧠A Tolerogenic #DCVax strategy for #Alzheimers https://t.co/YcwN0X813P $NWBO 🧠A Tolerogenic #DCVax strategy for #Alzheimers https://t.co/YcwN0X813P"
X Link 2026-02-14T23:19Z [----] followers, [---] engagements
"$NWBO $NWBO folk I just finished a v thorough evaluation of CHM Meeting & Approval Timelines of ALL NASs the MHRA assessed under the National Procedure pathway only in order to properly compare them to DCVax's current situation & timeline. Here are my findings: https://t.co/8xJ2UcOAnb $NWBO folk I just finished a v thorough evaluation of CHM Meeting & Approval Timelines of ALL NASs the MHRA assessed under the National Procedure pathway only in order to properly compare them to DCVax's current situation & timeline. Here are my findings: https://t.co/8xJ2UcOAnb"
X Link 2026-02-14T23:26Z [----] followers, [---] engagements
"$IBRX #ANKTIVA $IBRX IL-15 boosts lymphocyte survival/growth in lymphopenia powering CD8 T & NK cells. #ANKTIVA superagonist reverses it: 60% NSCLC patients hit ALC1500 mOS [----] mo (vs hist 7-9 mo chemo alone). $IBRX IL-15 boosts lymphocyte survival/growth in lymphopenia powering CD8 T & NK cells. #ANKTIVA superagonist reverses it: 60% NSCLC patients hit ALC1500 mOS [----] mo (vs hist 7-9 mo chemo alone)"
X Link 2026-02-14T23:26Z [----] followers, [---] engagements
"$HIMS $HIMS : Napster :: Ro : Spotify per @david_wainer WSJ https://t.co/abxydYw7sa $HIMS : Napster :: Ro : Spotify per @david_wainer WSJ https://t.co/abxydYw7sa"
X Link 2026-02-14T23:27Z [----] followers, [---] engagements
"$IBRX $IBRX- So what is the relevance of Feb 19th In the biotech world a stock price often moves on a "filing" because it marks a major de-risking event. Even though the FDA hasn't approved the drug yet the act of submitting the data pack tells investors several important things: $IBRX- So what is the relevance of Feb 19th In the biotech world a stock price often moves on a "filing" because it marks a major de-risking event. Even though the FDA hasn't approved the drug yet the act of submitting the data pack tells investors several important things:"
X Link 2026-02-14T23:29Z [----] followers, [---] engagements
"$NWBO #DCVax 🧬 The Trojan Vault: How $NWBO #DCVax #HealthBank Turns Tumor Banking Into Immune Infrastructure 📌 TLDR 🧊 HealthBank is not storage. It is custody. Tumor tissue preserved in viable format under regulated chain of identity becomes therapeutic-grade starting material. 🧬 https://t.co/Ymrf80xOH5 🧬 The Trojan Vault: How $NWBO #DCVax #HealthBank Turns Tumor Banking Into Immune Infrastructure 📌 TLDR 🧊 HealthBank is not storage. It is custody. Tumor tissue preserved in viable format under regulated chain of identity becomes therapeutic-grade starting material. 🧬"
X Link 2026-02-15T14:38Z [----] followers, [---] engagements
"$NWBO $NWBO https://t.co/YG0Hsh6ya5 TCG team has some interesting team members. Roger Perlmutter is currently a science partner. He was a science partner before as shown the following webpage dated in April [----]. https://t.co/DFMwRSpn02 Peter Svennilson as TCG founder used to serve https://t.co/H5vGp4ArE7 $NWBO https://t.co/YG0Hsh6ya5 TCG team has some interesting team members. Roger Perlmutter is currently a science partner. He was a science partner before as shown the following webpage dated in April [----]. https://t.co/DFMwRSpn02 Peter Svennilson as TCG founder used to serve"
X Link 2026-02-15T14:38Z [----] followers, [---] engagements
"$NWBO #DCVax 🌍 The Map That Makes Immunotherapy Stop Guessing 🧬 How Spatial Omics Turns $NWBO #DCVax into Programmable Infrastructure in #Glioblastoma and Across Cancer TLDR 📌 🗺 BRUCE turns immune failure into something you can see. It maps intact tumor tissue and asks the right https://t.co/a4yxfcqZMM 🌍 The Map That Makes Immunotherapy Stop Guessing 🧬 How Spatial Omics Turns $NWBO #DCVax into Programmable Infrastructure in #Glioblastoma and Across Cancer TLDR 📌 🗺 BRUCE turns immune failure into something you can see. It maps intact tumor tissue and asks the right"
X Link 2026-02-15T14:40Z [----] followers, [---] engagements
"$HIMS The stock price tells one story; the financials tell another. This is $HIMS. Does this look like a dying company to you https://t.co/FRgoyY0Zjx The stock price tells one story; the financials tell another. This is $HIMS. Does this look like a dying company to you https://t.co/FRgoyY0Zjx"
X Link 2026-02-15T14:42Z [----] followers, [---] engagements
"$OSCR $OSCR Morgan Stanley reports 42.84% increase in ownership of OSCR / Oscar Health Inc. On February [--] [----] - Morgan Stanley filed a 13F-HR form disclosing ownership of [-------] shares of Oscar Health Inc. (This was a notable buy in my books :) ) https://t.co/Ex5kRjBsEI $OSCR Morgan Stanley reports 42.84% increase in ownership of OSCR / Oscar Health Inc. On February [--] [----] - Morgan Stanley filed a 13F-HR form disclosing ownership of [-------] shares of Oscar Health Inc. (This was a notable buy in my books :) ) https://t.co/Ex5kRjBsEI"
X Link 2026-02-15T14:42Z [----] followers, [---] engagements
"$NWBO #DCVax 🧬 The $NWBO #DCVax Whole-Life Policy for Cancer: Immunity That Never Expires 📌 TLDR #Metastasis is the hidden liability in cancer. Even after the primary tumor is removed microscopic cells can escape hide and return years later. That is why metastasis drives most cancer https://t.co/vkuEnp3JQw 🧬 The $NWBO #DCVax Whole-Life Policy for Cancer: Immunity That Never Expires 📌 TLDR #Metastasis is the hidden liability in cancer. Even after the primary tumor is removed microscopic cells can escape hide and return years later. That is why metastasis drives most cancer"
X Link 2026-02-15T14:43Z [----] followers, [---] engagements
"$HIMS #GLP1 Everyone is talking about $HIMS and GLP-1 but no one is asking the real questions. How is Testosterone/Menopause scaling after its first quarter on the platform How much revenue has labs brought in since the launch in Q4 How will the business scale with international expansion https://t.co/AklPrKheVo Everyone is talking about $HIMS and GLP-1 but no one is asking the real questions. How is Testosterone/Menopause scaling after its first quarter on the platform How much revenue has labs brought in since the launch in Q4 How will the business scale with international expansion"
X Link 2026-02-15T14:43Z [----] followers, [---] engagements
"$IBRX $IBRX It was clear to me early on that Anktiva is so much more than just the drug that cures cancer. Its most likely something similar to the fountain of youth and health the ultimate longevity hack. The amazing miracles that Anktiva is able to deliver are not even $IBRX It was clear to me early on that Anktiva is so much more than just the drug that cures cancer. Its most likely something similar to the fountain of youth and health the ultimate longevity hack. The amazing miracles that Anktiva is able to deliver are not even"
X Link 2026-02-15T14:44Z [----] followers, [---] engagements
"$IBRX $IBRX One press release stating that they intend to file a BLA for lymphopenia and this stock (with the squeeze) goes to $20-$22. They have an RMAT process approved by the FDA almost [--] year ago. The data is overwhelming. The market is unlimited. They just need Dunkirk to be ready $IBRX One press release stating that they intend to file a BLA for lymphopenia and this stock (with the squeeze) goes to $20-$22. They have an RMAT process approved by the FDA almost [--] year ago. The data is overwhelming. The market is unlimited. They just need Dunkirk to be ready"
X Link 2026-02-15T14:49Z [----] followers, [---] engagements
"$IBRX $IBRX in Middle East Anktiva vs multiple tumors $IBRX in Middle East Anktiva vs multiple tumors"
X Link 2026-02-15T14:51Z [----] followers, [---] engagements
"$OSCR $OSCR Wow Morgan Stanley increased their Oscar Health position by 42% over [--] million shares at a cost of $92 million. 🚀🚀🚀🔥🔥🔥 $OSCR Wow Morgan Stanley increased their Oscar Health position by 42% over [--] million shares at a cost of $92 million. 🚀🚀🚀🔥🔥🔥"
X Link 2026-02-15T14:53Z [----] followers, [---] engagements
"Welcome to @AponiaAnalytics 🦉🦉🦉 Curious about how emerging diseases and breakthrough innovations shape tomorrows healthcare worldwide Follow along for the latest news real-time trends and unbiased analysis. 🦉📈💊⚕ Your provider of holistic intelligence in healthcare and biotech. We cover: - #BreakingNews in biotech medtech and healthcare. - Health threat reports emerging #diseases #outbreaks #epidemiology. - #MarketAnalysis - Trending companies and #startups. Follow us @aponia_analytics team 🦉🦉🦉"
X Link 2024-12-20T20:48Z [----] followers, 30.4K engagements
"$NVO Sarah Ketterer - Causeway Capital Management fund added bunch of $NVO (297871 shares) 🤑🤑 Looks like funds are adding $NVO rapidly. https://t.co/bT5U4EZ1jO Sarah Ketterer - Causeway Capital Management fund added bunch of $NVO (297871 shares) 🤑🤑 Looks like funds are adding $NVO rapidly. https://t.co/bT5U4EZ1jO"
X Link 2026-02-14T23:19Z [----] followers, [---] engagements
"$NVO $LLY $VKTX $NVO is aiming to capture around [--] million new patients when Medicare starts covering obesity treatments. $LLY $VKTX https://t.co/7BFpTkVtfj $NVO is aiming to capture around [--] million new patients when Medicare starts covering obesity treatments. $LLY $VKTX https://t.co/7BFpTkVtfj"
X Link 2026-02-14T23:24Z [----] followers, [---] engagements
"$NVO Motley Fool: Got $500 Buy and hold forever and $NVO made the list. They highlight Novo as a rare combo: high-growth healthcare + low valuation. GLP-1 leader with Wegovy Ozempic Rybelsus Obesity sales +26% in FY25 GLP-1 market seen reaching $254B by [----] Motley Fool: Got $500 Buy and hold forever and $NVO made the list. They highlight Novo as a rare combo: high-growth healthcare + low valuation. GLP-1 leader with Wegovy Ozempic Rybelsus Obesity sales +26% in FY25 GLP-1 market seen reaching $254B by 2034"
X Link 2026-02-14T23:29Z [----] followers, [---] engagements
"$LLY $NVO Good oral wegovy #s this morning. $LLY and $NVO both responding well. These drugs are going to do huge numbers. They ARE worse drugs but Im telling you - people youd never imagine wanting a GLP1 are going to be popping these pills. Discontinuation rates will be high. Its Good oral wegovy #s this morning. $LLY and $NVO both responding well. These drugs are going to do huge numbers. They ARE worse drugs but Im telling you - people youd never imagine wanting a GLP1 are going to be popping these pills. Discontinuation rates will be high. Its"
X Link 2026-02-14T23:31Z [----] followers, [---] engagements
"$IBRX $IBRX Can Anktiva Cure HIV We are going to find out. First use ART to drive the virus to undetectable. (NCT07145164) Then stop ART and give Anktiva. Let's see if the viral levels come back. If it doesn't then we have a $1Trillion company. $IBRX Can Anktiva Cure HIV We are going to find out. First use ART to drive the virus to undetectable. (NCT07145164) Then stop ART and give Anktiva. Let's see if the viral levels come back. If it doesn't then we have a $1Trillion company"
X Link 2026-02-15T14:48Z [----] followers, [---] engagements
"$HIMS $NVO I have a cope scenario of 4D chess for $HIMS folks: $HIMS does a stupid thing like it did with the Wegovy pill $NVO will be like wtf lawsuit FDA and US govt will be like wtf all compounded BS is banned All compounders are dead thanks to Hims $NVO terminates the https://t.co/qoqhQXOy5F I have a cope scenario of 4D chess for $HIMS folks: $HIMS does a stupid thing like it did with the Wegovy pill $NVO will be like wtf lawsuit FDA and US govt will be like wtf all compounded BS is banned All compounders are dead thanks to Hims $NVO terminates the https://t.co/qoqhQXOy5F"
X Link 2026-02-15T19:47Z [----] followers, [---] engagements
"$HIMS $NKE $AAPL $HIMS While people worry about the stock price declines Hims is busy trying to become a consumer healthcare brand more like $NKE or $AAPL than a traditional pharma company. Great companies focus on decades not on quarters. $HIMS While people worry about the stock price declines Hims is busy trying to become a consumer healthcare brand more like $NKE or $AAPL than a traditional pharma company. Great companies focus on decades not on quarters"
X Link 2026-02-15T19:54Z [----] followers, [---] engagements
"$IBRX $IBRX is a $250 stock trading at $6 $IBRX is a $250 stock trading at $6"
X Link 2026-02-16T20:54Z [----] followers, [---] engagements
"$HIMS What is a biomarker test $HIMS biomarker tests are in depth at home or lab based blood tests that measure up to [---] health markers. These panels analyze metabolic hormonal immune and cardiovascular health to provide a personalized expert backed action plan for improving https://t.co/fztJFP33P6 What is a biomarker test $HIMS biomarker tests are in depth at home or lab based blood tests that measure up to [---] health markers. These panels analyze metabolic hormonal immune and cardiovascular health to provide a personalized expert backed action plan for improving https://t.co/fztJFP33P6"
X Link 2026-02-16T20:54Z [----] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing